Podcasts about arpa h

What if a government agency could fund transformative health research with $200 million budgets and no bureaucratic committees? In this talk, Jean Hebert explores ARPA-H's – a research funding agency – unique mission to accelerate health breakthroughs, from 3D-printed organs to functional eye transplants. He covers how ARPA-H operates differently from traditional government funding through autonomous program managers, why it presents exceptional opportunities for longevity researchers, and how both established scientists and entrepreneurs can engage with this well-funded agency that's aligned with life extension goals.Jean Hebert is a professor of genetics and neuroscience, and the author of "Replacing Aging". He currently serves as a Program Manager at ARPA-H. His personal mission remains unchanged: to beat aging, which he believes is achievable through replacement therapies and transformative approaches to life extension.This talk was recorded at Vision Weekend US 2024. To see the slides and more talks from the event, please visit our Youtube channel. Hosted on Acast. See acast.com/privacy for more information.

In this episode of BioTalk, Sam Tetlow, Founder and CEO of Grant Engine, joins the conversation to unpack how companies can successfully navigate the rapidly changing world of non-dilutive funding. With continued resolutions, shifting agency priorities, and evolving leadership at HHS and beyond, 2025 presents both new hurdles and new opportunities for biotech and health innovators. Sam shares actionable insights on what's changed under the current administration, where funding gaps exist, and how early-stage companies can align proposals with both individual program officers and federal leadership. He also offers proven strategies for building champions, writing competitive applications, and thinking differently about the grant process in today's environment.   Sam Tetlow is the Founder and CEO of Grant Engine, where he leads a team focused on securing funding for leading life science companies through SBIR, BARDA, ARPA-H, NIH, DoD, and NSF opportunities. A serial entrepreneur and experienced investor, Sam has contributed to the success of companies like EpiCypher, Gentris Corporation, and Tranzyme Pharma (IPO in 2011). With over two decades of experience and a 6.2x return on invested capital, he brings deep knowledge of the strategic, financial, and technical aspects of life science commercialization. Sam holds a B.S. in Aerospace Engineering from Worcester Polytechnic Institute and an MBA from UNC's Kenan-Flagler Business School. Editing and post-production work for this episode was provided by The Podcast Consultant.

00:04:20 - 00:14:25: FBI's Role in January 6 and Lack of TransparencyKash Patel and Dan Bongino's evasive responses on FBI's involvement in January 6, suggesting a deep state operation. Critique of their alignment with the party line, lack of clarity, and distrust in forthcoming information being filtered through Congress. Mentions Jeffrey Epstein's death as a non-suicide, reflecting broader skepticism of official narratives.00:31:50 - 00:42:13: Media Manipulation and PropagandaDiscussion of Caitlin Johnstone's article on how Western media uses distortions, emphasis, and omissions to shape narratives, particularly on Israel-Palestine. Emphasis on the need to focus on raw data to counter manipulation, with examples of underreported issues like starvation in Gaza versus overreported stories like Russia-Ukraine.00:46:29 - 00:59:40: Lab-Grown Meat as a Control MechanismCritique of lab-grown meat as a tool for corporate control, removing self-sufficiency in food production. Discussion of its ethical and environmental claims as hollow, with concerns about engineered scarcity and dependence on conglomerates. Mentions the unappetizing nature of lab-grown products like the “world's largest cultivated chicken nugget.”01:13:29 - 01:17:16: Montana's Ban on Warrantless Data PurchasesMontana's Senate Bill 282 prohibits law enforcement from buying personal data (e.g., geolocation, financial records) without a warrant, closing the data broker loophole. Critique of government's data buying/selling practices, with DMVs profiting millions (e.g., Florida: $77M, California: $52M in 2017).01:19:55 - 01:26:01: Meta's Facial Recognition Glasses and Surveillance RisksMeta plans to integrate facial recognition into Ray-Ban smart glasses, enabling real-time identification of passersby, raising severe privacy concerns. Unlike fixed cameras, mobile glasses are harder to detect, potentially enabling mass surveillance by individuals or government.01:27:35 - 01:37:47: Transphobia Investigation Over Lucy SkeletonBrazilian woman faces up to three years in prison for calling Lucy the skeleton female, deemed transphobic by activists who argue ancient fossils could have had modern gender identities. Critique of this as an attack on objective reality and scientific fact.01:55:04 - 02:00:25: Israel's Ethnic Cleansing and Occupation of GazaNetanyahu admits to ethnic cleansing goals in Gaza, citing destruction of homes and lack of countries accepting Palestinian refugees. Israel's blockade and use of food to lure starving civilians criticized as inhumane, with growing disapproval even among Republicans (Pew: 37% unfavorable views by 2025).02:00:42 - 02:12:27: Measles Panic and Vaccine DangersMedia exaggerates measles as the “world's most infectious disease” (e.g., one DC case, 300 in Texas out of 31 million). Child's death misattributed to measles was due to medical error (delayed antibiotics for pneumonia). Critique of vaccine schedules causing autism/allergies and mercury (thimerosal) in vaccines, requiring hazmat cleanup but injected into children.02:17:42 - 02:34:50: Susan Monterey's CDC Appointment and Biosecurity ConcernsSusan Monterey, appointed CDC director, criticized for biosecurity ties (ARPA-H, BARDA, DARPA) and vaccine advocacy. RFK Jr.'s endorsement as a Maha supporter questioned as a betrayal, given her support for AI-driven health projects (e.g., predicting diseases from personal data) and high-risk biomedical research, likened to pandemic manufacturing.02:34:50 - 02:42:09: NGOs and Government Funding Woke IdeologyUS government (CIA, USAID) and NGOs (Ford, Rockefeller Foundations) funded gay pride and transgenderism since the 1980s, evolving into woke ideology. Framed as a satanic agenda to destroy Western civilization, driven by spiritual forces beyond earthly institutions, with government as a tool of higher powers.02:47:22 - 03:03:14: Biological Computers and Brain-Computer InterfacesCortical Labs' Cow One uses human brain cells for neural networks, trained to play Pong, with potential for drug testing. DARPA, NIH, and Obama's BRAIN Initiative fund BCIs for military applications (e.g., memory transfer, neuro-weapons), raising concerns about mind control, transhumanism, and technocratic control via public-private partnerships.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

00:04:20 - 00:14:25: FBI's Role in January 6 and Lack of TransparencyKash Patel and Dan Bongino's evasive responses on FBI's involvement in January 6, suggesting a deep state operation. Critique of their alignment with the party line, lack of clarity, and distrust in forthcoming information being filtered through Congress. Mentions Jeffrey Epstein's death as a non-suicide, reflecting broader skepticism of official narratives.00:31:50 - 00:42:13: Media Manipulation and PropagandaDiscussion of Caitlin Johnstone's article on how Western media uses distortions, emphasis, and omissions to shape narratives, particularly on Israel-Palestine. Emphasis on the need to focus on raw data to counter manipulation, with examples of underreported issues like starvation in Gaza versus overreported stories like Russia-Ukraine.00:46:29 - 00:59:40: Lab-Grown Meat as a Control MechanismCritique of lab-grown meat as a tool for corporate control, removing self-sufficiency in food production. Discussion of its ethical and environmental claims as hollow, with concerns about engineered scarcity and dependence on conglomerates. Mentions the unappetizing nature of lab-grown products like the “world's largest cultivated chicken nugget.”01:13:29 - 01:17:16: Montana's Ban on Warrantless Data PurchasesMontana's Senate Bill 282 prohibits law enforcement from buying personal data (e.g., geolocation, financial records) without a warrant, closing the data broker loophole. Critique of government's data buying/selling practices, with DMVs profiting millions (e.g., Florida: $77M, California: $52M in 2017).01:19:55 - 01:26:01: Meta's Facial Recognition Glasses and Surveillance RisksMeta plans to integrate facial recognition into Ray-Ban smart glasses, enabling real-time identification of passersby, raising severe privacy concerns. Unlike fixed cameras, mobile glasses are harder to detect, potentially enabling mass surveillance by individuals or government.01:27:35 - 01:37:47: Transphobia Investigation Over Lucy SkeletonBrazilian woman faces up to three years in prison for calling Lucy the skeleton female, deemed transphobic by activists who argue ancient fossils could have had modern gender identities. Critique of this as an attack on objective reality and scientific fact.01:55:04 - 02:00:25: Israel's Ethnic Cleansing and Occupation of GazaNetanyahu admits to ethnic cleansing goals in Gaza, citing destruction of homes and lack of countries accepting Palestinian refugees. Israel's blockade and use of food to lure starving civilians criticized as inhumane, with growing disapproval even among Republicans (Pew: 37% unfavorable views by 2025).02:00:42 - 02:12:27: Measles Panic and Vaccine DangersMedia exaggerates measles as the “world's most infectious disease” (e.g., one DC case, 300 in Texas out of 31 million). Child's death misattributed to measles was due to medical error (delayed antibiotics for pneumonia). Critique of vaccine schedules causing autism/allergies and mercury (thimerosal) in vaccines, requiring hazmat cleanup but injected into children.02:17:42 - 02:34:50: Susan Monterey's CDC Appointment and Biosecurity ConcernsSusan Monterey, appointed CDC director, criticized for biosecurity ties (ARPA-H, BARDA, DARPA) and vaccine advocacy. RFK Jr.'s endorsement as a Maha supporter questioned as a betrayal, given her support for AI-driven health projects (e.g., predicting diseases from personal data) and high-risk biomedical research, likened to pandemic manufacturing.02:34:50 - 02:42:09: NGOs and Government Funding Woke IdeologyUS government (CIA, USAID) and NGOs (Ford, Rockefeller Foundations) funded gay pride and transgenderism since the 1980s, evolving into woke ideology. Framed as a satanic agenda to destroy Western civilization, driven by spiritual forces beyond earthly institutions, with government as a tool of higher powers.02:47:22 - 03:03:14: Biological Computers and Brain-Computer InterfacesCortical Labs' Cow One uses human brain cells for neural networks, trained to play Pong, with potential for drug testing. DARPA, NIH, and Obama's BRAIN Initiative fund BCIs for military applications (e.g., memory transfer, neuro-weapons), raising concerns about mind control, transhumanism, and technocratic control via public-private partnerships.Follow the show on Kick and watch live every weekday 9:00am EST – 12:00pm EST https://kick.com/davidknightshow Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Time Stamps:2:00 - Siemens Executives Die in Helicopter Crash11:03 - ARPA-H and the AI Healthcare Revolution41:14 - Larry Ellison = Trump's Media Mogul?1:02:15 - US & Iran Negotiations/Regime Change in Iran?1:12:11 - Ukraine/Russia Truce Violations1:16:59 - REAL ID Requirement1:45:53 - "The Maniac Murder Cult"Welcome to The Morning Dump, where we dive headfirst into the deep end of the pool of current events, conspiracy, and everything in between. Join us for a no-holds-barred look at the week's hottest topics, where we flush away the fluff and get straight to the substance.Please consider supporting our work-Austin's Patreon: https://www.patreon.com/c/TheUnderclassPodcastAustin's Spreaker: https://www.spreaker.com/podcast/the-underclass-podcast--6511540Austin's Rumble: https://rumble.com/user/TheUnderclassPodcastAustin's YouTube: https://www.youtube.com/@TheUnderclassPodcastCheck out nadeaushaveco.com today & use code Jose for 10% off your entire order!!!Jose's Patreon- https://www.patreon.com/nowayjose2020 Only costs $2/month and will get you access to episodes earlier than the public Check out TopLobsta's kickass threads- toplobsta.com Use JOSE at checkout for 10% off Get No Way, Jose! merch- https://www.toplobsta.com/pages/no-way-joseNo Way, Jose! Rumble Channel- https://rumble.com/c/c-3379274No Way, Jose! Odysee Channel- https://odysee.com/@NoWayJose:7?r=JChxx9RMmW9PuL49z3PvTq4sxE2GjJrpNo Way, Jose! YouTube Channel- https://youtube.com/channel/UCzyrpy3eo37eiRTq0cXff0gJose's Podcast Host- https://redcircle.com/shows/no-way-joseApple podcasts- https://podcasts.apple.com/us/podcast/no-way-jose/id1546040443Spotify- https://open.spotify.com/show/0xUIH4pZ0tM1UxARxPe6ThStitcher- https://www.stitcher.com/show/no-way-jose-2Amazon Music- https://music.amazon.com/podcasts/41237e28-c365-491c-9a31-2c6ef874d89d/No-Way-JoseGoogle Podcasts- https://www.google.com/podcasts?feed=aHR0cHM6Ly9mZWVkcy5yZWRjaXJjbGUuY29tL2ZkM2JkYTE3LTg2OTEtNDc5Ny05Mzc2LTc1M2ExZTE4NGQ5Yw%3D%3DRadioPublic- https://radiopublic.com/no-way-jose-6p1BAOVurbl- https://vurbl.com/station/4qHi6pyWP9B/#REALIDRequirement #ManiacMurderCult #MKU #MKY #O9A #TrumpAssassinationPlot #NikitaCasap #SiemensCrash #HelicopterTragedy #SiemensExecutives #ARPAHTranshumanism #AIHealthcareRevolution #DARPATV #InternetOfBodies #MRNABioWeapon #ModernEugenics #AIGovernance #PredictiveMedicine #LarryEllison #TrumpMediaMogul #EllisonTrump #EllisonTikTok #USIranTalks #IranRegimeChange #IranNegotiations #TruceViolations #RussiaUkraineConflictBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-underclass-podcast--6511540/support.

In this episode of Lab Rats to Unicorns, we welcome Dede Willis, co-founder and CEO of Orbit Genomics, a trailblazer in the field of diagnostics and life sciences. With a background in aerospace engineering and over 25 years of leadership experience, Dede shares how her engineering mindset and entrepreneurial resilience have driven her to build impactful startups that tackle complex challenges. Dede dives into the mission of Orbit Genomics, exploring how they're harnessing the potential of “junk DNA” to revolutionize cancer detection and save lives. She also opens up about the challenges of securing funding in the diagnostics space, the importance of fostering team diversity, and the pivotal role government programs like ARPA-H and Cancer Moonshot play in advancing healthcare innovation. Through thoughtful storytelling and actionable insights, Dede reveals how diagnostics can complement therapeutics, why collaboration is essential to progress, and how startups can thrive by embracing resilience and adaptability. This episode is an inspiring testament to the power of persistence, innovation, and building bridges in science and beyond.

The Advanced Research Projects Agency - Health, known as ARPA-H, is tiny at only 118 employees. Its personnel needs are highly specific, though. ARPA-H has used a variety of strategies to get the people it needs. The Government Accountability Office finds, the agency needs a more organized approach. More now from the GAO's director of science, technology assessment and analytics, Candice Wright. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Advanced Research Projects Agency - Health, known as ARPA-H, is tiny at only 118 employees. Its personnel needs are highly specific, though. ARPA-H has used a variety of strategies to get the people it needs. The Government Accountability Office finds, the agency needs a more organized approach. More now from the GAO's director of science, technology assessment and analytics, Candice Wright. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. Andrew Brack, Program Manager at the Advanced Research Projects Agency for Health (ARPA-H), discusses PROSPR (Proactive Solutions for Prolonging Resilience), an ambitious new program aimed at extending human healthspan. In this wide-ranging conversation, Chris and Andrew explore how PROSPR plans to accelerate the development of therapies that target aging itself by building the regulatory and scientific infrastructure needed to measure and improve health during aging. They discuss PROSPR's innovative approaches to in-home data collection, biomarker development, and clinical trial design that could compress decades-long studies into just three years.The Finer Details:The mission and structure of ARPA-H as a catalyst for healthcare innovationHow PROSPR aims to build "train tracks" for the longevity therapeutics industryThe program's novel approach to measuring health through intrinsic capacityStrategies for compressing clinical trials from decades to yearsThe economic impact of extending healthspan by just one yearPlans for first- and second-generation therapeutics targeting agingThe role of in-home health monitoring in future clinical trialsQuote: "We have this moral imperative to close the gap between the length that we are living and the number of years that we're living in good health."Links:PROSPR websiteProposers' Day registration

President Joe Biden will issue a memo and framework on the use of AI in the context of national security Thursday, with the aim of providing steps for U.S. leadership and guardrails for governance of the technology. Under the memo, agencies will be directed to access “the most powerful AI systems and put them to use,” senior administration officials who briefed reporters on the memo ahead of its release said. The memo will also bolster the role of the AI Safety Institute and provide direction to agencies for AI use for national security. The Advanced Research Projects Agency for Health, known as ARPA-H, is seeking information about how autonomous artificial intelligence systems, known as agentic AI, might be used in the health care space. A recent request for information posted by the Department of Health and Human Services agency specifically asks for information on implementations of agentic AI, how multiple agentic AI systems work together, scalability, risks, and how autonomy is decided, among other things. The Daily Scoop Podcast is available every Monday-Friday afternoon. If you want to hear more of the latest from Washington, subscribe to The Daily Scoop Podcast on on Apple Podcasts, Soundcloud, Spotify and YouTube.

The Advanced Research Projects Agency-Health, ARPA-H, has launched two new programs aimed at the kinds of tough problems the agency specializes in. One deals with artificial intelligence models to predict drug safety. The other with computation systems needed to design vaccines. Details now from ARPA-H program manager Dr. Andy Kilianskhttps://arpa-h.gov/news-and-events/arpa-h-launches-program-develop-predictive-drug-safety-and-efficacy-modelshttps://arpa-h.gov/news-and-events/arpa-h-announces-awards-develop-computational-platform-multi-virus-vaccine-design Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Advanced Research Projects Agency-Health, ARPA-H, has launched two new programs aimed at the kinds of tough problems the agency specializes in. One deals with artificial intelligence models to predict drug safety. The other with computation systems needed to design vaccines. Details now from ARPA-H program manager Dr. Andy Kiliansk https://arpa-h.gov/news-and-events/arpa-h-launches-program-develop-predictive-drug-safety-and-efficacy-models https://arpa-h.gov/news-and-events/arpa-h-announces-awards-develop-computational-platform-multi-virus-vaccine-design Learn more about your ad choices. Visit podcastchoices.com/adchoices

The Advanced Research Projects Agency for Health (ARPA-H) has launched a new program providing health care organizations a rapid and secure cyber solution that will protect their infrastructure from threats and prevent disruptions in patient care. ARPA-H Resilient Systems Program Manager Andrew Carney discusses the Universal Patching Intermediation for Autonomous Defense (UPGRADE) program and how it offers medical facilities protection from ransomware attacks by automatically providing proactive and scalable updates to their IT systems. Carney highlighted another ARPA-H program called the Digital Health Security Initiative (DIGIHEALS) that's addressing vulnerabilities in data security. He also shared details about the agency's collaborative efforts with its defense counterpart, DARPA.

Artificial intelligence has penetrated deeply into the world of medical devices. The DA has approved nearly a thousand AI-enabled medical gadgets. Given that nature of AI, the question must be asked: How to keep these devices working properly overtime. That's a question the Advanced Research Projects Agency for Health seeks to answer. For details, we turn to ARPA-H program manager Berkman Sahiner. Learn more about your ad choices. Visit megaphone.fm/adchoices

Artificial intelligence has penetrated deeply into the world of medical devices. The DA has approved nearly a thousand AI-enabled medical gadgets. Given that nature of AI, the question must be asked: How to keep these devices working properly overtime. That's a question the Advanced Research Projects Agency for Health seeks to answer. For details, we turn to ARPA-H program manager Berkman Sahiner. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Government systems often take a lot of flack for their (sometimes) built-in inability to take risks and make big bets. So, what would it take to encourage the government to take those big, risky moonshots? For Health, that's the role of ARPA-H – to fund new ways of improving health by investing in people with big ideas. We sat down with ARPA-H Director Renee Wegrzyn at Aspen Ideas Health to talk about how it's going and what comes next. We discuss:Why ARPA-H is personal for President Biden.How ARPA-H's special authorities – from flexible hiring to novel contracting – are its secret weapons for speed and scale.The critical role of Program Managers – single decision maker driving the vision and execution of each $50-$200 million initiative.Renee says ARPA-H gives her the ability to direct funds into areas that are sometimes left off the list of “must haves” for innovation:“...one of the only top down things I've done as a director is said, ‘Why aren't we funding more in women's health? We don't have any program managers in the pipeline that want to exclusively focus on this'. But I think we all inherently understand that women are underrepresented in almost every aspect of health. So I asked our [Program Managers].. who wants to raise [a] hand and pick a topic that is really either unique to women, or is disproportionately affecting women that we can do a sprint and invest around. And so I got six Program Managers to come up with topics, everything from Women's Health at home, to brain health, to understanding and quantifying pain – and through the Investor Catalyst Hub we have worked with investors to understand what kind of convincing scale do we need to get to for you to be the second investor. And we competed this across the country.”Relevant LinksAbout ARPA-H ARPA-H Health Equity Factsheet The Minor Consult Podcast EpisodeARPA - H TimelineYoutube Conversation with New Yorker writerWhite House FAQ Sheet on ARPA-HAbout Our GuestDr. Renee Wegrzyn is the first director of the Advanced Research Projects Agency for Health (ARPA-H), appointed by President Biden on October 11, 2022. Previously, she was the Vice President of Business Development at Ginkgo Bioworks and Head of Innovation at Concentric by Ginkgo, where she focused on synthetic biology for combating infectious diseases like COVID-19.Wegrzyn has experience with DARPA and IARPA, the models for ARPA-H. At DARPA, she used synthetic biology and gene editing to enhance biosecurity and the bioeconomy, managing programs like Living Foundries, Safe Genes, PREPARE, and DIGET. She received the Superior Public Service Medal for her DARPA work. Her career includes leading biosecurity and gene therapy teams in private industry, developing immunoassays and diagnostics. Wegrzyn has served on various scientific advisory boards, including those for the National Academies and the Air Force Research Labs. She holds a Ph.D. and a bachelor's degree in applied biology from the Georgia Institute of Technology and completed...

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Viral vector manufacturers are facing challenges such as high production expenses, low titers, empty capsids, and limited scalability when producing cell and gene therapies. To overcome these challenges, they are turning to next generation production processes to create a cost-effective and robust AAV manufacturing process. This new approach aims to produce higher titers and full capsids, increase efficiencies resulting from high yields, and drive down the cost per dose. By implementing these strategies, manufacturers can improve the productivity of AAV production and bring promising treatments to the market more effectively.Embecta received FDA approval for its insulin patch pump, featuring a larger insulin reservoir based on feedback from people with type 2 diabetes. Meanwhile, Illumina avoided a fine for its acquisition of Grail in a European court victory. The ARPA-H program will focus on AI degradation in medical tools, while a pathology group is suing to block an FDA lab test rule. Additionally, Medtronic's chief medical officer of acute care and monitoring has departed for a new role.The text discusses various updates in the biopharma industry as of September 3, 2024. It covers topics such as the next challenger to Prevner, advancements in AI drug discovery, concerns over suicide risk of obesity drugs, Recursion's lead drug safety, Vaxcyte's positive data for a pneumococcal vaccine, Sanofi's mixed results in MS drug trials, and the value of digital insights in pharma success.A new study predicts a healthcare labor shortage by 2028, with certain states and specialties facing acute shortages. The study also reveals disparities in fighting medical bills, as uninsured and less educated patients are less likely to question their bills. The ARPA-H program will focus on addressing AI degradation in medical tools. Other updates include tracking healthcare worker strikes and data breaches. The use of technology is transforming healthcare to combat challenges such as workforce shortages and shifting care utilization patterns.FDA Commissioner Dr. Robert Califf is considering reforms to advisory committees, including potentially scrapping expert voting in some circumstances. Califf believes that the discussions within these committees may be more valuable to the FDA than the final vote outcomes. Eliminating voting could help clarify the role of advisory committees. Other potential reforms being discussed include addressing conflicts of interest.The text discusses the importance of getting the Institutional Review Board (IRB) review right the first time and introduces a checklist of critical questions to ask potential IRB partners to ensure a smoother review process. By asking the right questions and choosing the right IRB, the review process can be more efficient and effective.Novo Nordisk's drug Ozempic will continue to face shortages into the fourth quarter due to supply issues, even as the company tries to expand its indication. Astellas Gene Therapies is closing its biomanufacturing facility in San Francisco, affecting about 100 employees and shifting manufacturing to North Carolina.In a landscape where consumers are willing to switch brands to save money, it is crucial for brands to establish and maintain loyalty among shoppers. By leading with value, moving consumers from awareness to loyalty to advocacy, and creating connection and community, brands can build brand love even in the face of economic pressures.The text discusses how emerging oncology innovations have led to more effective therapies for cancer patients. The increased investment in cancer research has introduced new treatments such as cell and gene therapies, antibody drug conjugates, and checkpoint inhibitors. Despite these advancements, the industry still faces challenges in expanding access and improving outcomes.

In this episode of Innovate and Elevate, Sharon Kedar is joined by Dr. Renee Wegrzyn, the inaugural director of the Advanced Research Projects Agency for Health (ARPA-H), a government agency designed to drive high-impact health innovations. Appointed by President Biden in 2022, Dr. Wegrzyn shares her deep experience in both synthetic biology and biosecurity, drawing from her work at DARPA, IARPA, and Ginkgo Bioworks.The conversation dives into the unique role of government in fostering breakthrough technologies, emphasizing ARPA-H's mission to transform health outcomes. Dr. Wegrzyn explains how ARPA-H takes on ambitious, high-risk projects with the potential to revolutionize healthcare, much like DARPA's past successes in defense technologies, such as the early development of mRNA technology.Dr. Wegrzyn highlights ARPA-H's approach to maximizing the return on investment for American taxpayers by focusing on scalable, impactful solutions that can transition to the private sector. She walks listeners through transformative projects, including NITRO, GLIDE, ADAPT, and POSEIDON. ARPA-H has a unique Program Management structure, which provides hands-on mentorship and support to ARPA-H grantees. Dr. Wegrzyn identifies how the partnership helps innovators address cost, accessibility, and user experience in health innovations. Sharon and Dr. Wegrzyn also discuss the ARPA-H's Sprint for Women's Health and how the funding opportunity addresses critical unmet challenges in the women's health sector. Episode Outline(01:50) How the US Government Drives Innovation (04:01) The Return on Investment to Americans (09:27) ARPA-H Programs and Funding (12:42) How To Work with ARPA-H (15:28) The Audacity to Imagine Success (18:59) Improving Research and the Standard of Care (21:40) Women's Health Innovation (26:45) Beyond Conversation: Embracing Data-Driven Solutions Connect with SharonConnect with Sharon on LinkedIn: Sharon KedarLearn more about Innovate and Elevate innovateandelevatepodcast.comSubscribe to Innovate and Elevate on YouTubeJoin the newsletter to receive the latest episodes in your inbox: Innovate and Elevate NewsletterConnect with Dr. Renee WegrzynFollow Renee on LinkedInLearn more on the ARPA-H websiteAdditional ResourcesSubscribe to the ARPA-H Vitals newsletterFull list of ARPA-H programsThe hidden questions behind the Heilmeir QuestionsThe White House Initiative on Women's Health ResearchThis podcast is produced by the women at

Don Kinzler shares fall gardening tips. Dr. Renee Wegrzyn discusses ARPA-H's bold health initiatives on "Conversations on Health Care" and and Chuck Lura explores North Dakota's iconic sunflowers.

The director of the Advanced Research Projects Agency for Health (ARPA-H) knows the eyes of the nation are on her. Renee Wegrzyn, Ph.D., leads the billion-dollar effort charged with leveraging research advances for real-world impact. Wegrzyn talked with hosts Mark Masselli and Margaret Flinter at Aspen Ideas: Health about the agency's initiatives, including a $100 million sprint for women's health and creating tissue-specific delivery of therapies. “How can we pursue some of these breakthroughs — in our case, for health — by empowering the scientists…the program managers…that have these really big ideas that are so risky that the technical sector, the private sector can't address because there's no proof of concept?” She explained the process: Hire program managers with big ideas in health and give them a time frame to find solutions. Wegrzyn said the time limit ensures they bring a sense of urgency to solving problems. In return, participants get resources to focus on technical risks. Many of ARPA-H's missions are cancer-centered, aimed at issues through what-if questions such as: “What if cancer surgeries were one-and-done?” “What if clinical trials evolved in the same way tumors do?” She said, “The investments that we've made in cancer [include] our precision surgical interventions program. Think about reimagining the operating room suites, when a surgeon is looking into a surgical cavity and trying to remove a tumor.”

The director of the Advanced Research Projects Agency for Health (ARPA-H) knows the eyes of the nation are on her. Renee Wegrzyn, Ph.D., leads the billion-dollar effort charged with leveraging research advances for real-world impact.Wegrzyn talked with hosts Mark Masselli and Margaret Flinter at Aspen Ideas: Health about the agency's initiatives, including a $100 million sprint for women's health and creating tissue-specific delivery of therapies.“How can we pursue some of these breakthroughs — in our case, for health — by empowering the scientists…the program managers…that have these really big ideas that are so risky that the technical sector, the private sector can't address because there's no proof of concept?”She explained the process: Hire program managers with big ideas in health and give them a time frame to find solutions.Wegrzyn said the time limit ensures they bring a sense of urgency to solving problems. In return, participants get resources to focus on technical risks.Many of ARPA-H's missions are cancer-centered, aimed at issues through what-if questions such as: “What if cancer surgeries were one-and-done?” “What if clinical trials evolved in the same way tumors do?”She said, “The investments that we've made in cancer [include] our precision surgical interventions program. Think about reimagining the operating room suites, when a surgeon is looking into a surgical cavity and trying to remove a tumor.” Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

August 5, 2024: Wes Wright, Chief Healthcare Officer at Ordr, and Mac McMillan, Founder, CEO, Board Member, and Advisor, join Drex for the news. The discussion highlights the persistent disparity in healthcare access between rural and urban areas, questioning whether technology alone can bridge this gap. The conversation also explores the ARPA-H initiative, pondering if new technology development is necessary when existing tools might suffice. The trio reflects on the creation of a dedicated Cyber Force, drawing parallels with military coordination to enhance cybersecurity. Should the government play a more significant role in supporting private sector defenses? They further discuss the indictment of a North Korean cybercriminal, debating the implications of such actions and the broader geopolitical context.Key Points:00:37 Rural Healthcare Challenges02:54 Technology and Socioeconomic Issues05:58 ARPA-H Initiative and Military Healthcare09:17 The Case for a Cyber Force13:54 North Korean Cyber Threats and Final ThoughtsNews articles:Microsoft and Google are helping rural hospitals protect themselves from cyberattacksUS indicts North Korean hacker accused of helping extort US hospitals | CNN PoliticsA Cyber Force Is Not the Only Solution - War on the RocksThis Week Health SubscribeThis Week Health TwitterThis Week Health LinkedinAlex's Lemonade Stand: Foundation for Childhood Cancer Donate

In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., welcomes guests from ARPA-H: Craig Gravitz, Director of the Project Accelerator Transition Innovation Office (PATIO), and Jenica Patterson, Ph.D., Portfolio Lead at ARPA-H. Together, they provide a comprehensive overview of ARPA-H's mission and innovative programs.   Craig Gravitz and Jenica Patterson share their educational and career backgrounds, setting the stage for a discussion about ARPA-H and its various initiatives. They provide insights into how ARPA-H differentiates itself from other agencies like HHS and NIH, while also highlighting their collaborative efforts.   Listeners will learn about the Project Accelerator Transition Innovation Office (PATIO) and its crucial role within ARPA-H. Jenica Patterson discusses her portfolio, including key areas and projects, and provides details on the new women's sprint for health initiative and its funding tracks.   The conversation highlights examples of ARPA-H investments and milestones achieved, as well as the processes involved in determining future programs and investment priorities. Craig and Jenica also discuss the unique Entrepreneur in Residence (EIR) program and how it supports ARPA-H projects.   About Craig Gravitz: Craig Gravitz is designing and implementing the transition and commercial strategy for the Advanced Research Projects Agency for Health (ARPA-H).  Prior to joining ARPA-H, Mr. Gravitz launched and ran a research and development program at the Defense Logistics Agency. He is a licensed attorney and has previously serviced as a contracting officer.   About Jenica Patterson, Ph.D.: Jenica Patterson, Ph.D is a Portfolio Lead at ARPA-H within the Project Accelerator Transition Innovation Office (PATIO) and leads the Sprint for Women's Health. Formerly Dr. Patterson served as the Director of the Technology Transfer and Transition (T3X) Division in the PATIO office, where she oversaw public-private partnerships for transition and the small business program for ARPA-H. Dr. Patterson received her Ph.D in Neuroscience at the University of Maryland, Baltimore County (UMBC) and served as a Science and Technical Advisor at the Defense Advance Research Project Agency, and a Program Director at NIH prior to joining ARPA-H.   Tune in to BioTalk for an informative discussion with Craig Gravitz and Jenica Patterson as we explore the innovative work of ARPA-H and its impact on health research and development.

I discuss Crowdstrike and their history, along with the Q drops that describe their intentions and what the shutdown may have really been about; I discuss the company Palantir and the work of Whitney Webb and her dig on their connections to mass surveillance and pre-crime; I also dive briefly into their sister companies Carbyne and ARPA-H and how they are designed to surveil and socially engineer the masses to ultimately kill us.  Crowdstrike: https://archive.4plebs.org/pol/thread/474868046 Palantir https://theamericanclassroom.substack.com/p/palantir-mass-surveillance-and-pre

This podcast is about big ideas on how technology is making life better for people with vision loss. For hundreds of years, health professionals have dreamed of restoring vision for people who are blind or visually impaired. However, doing so, either through transplanting a functioning eye or using technological aids, is an incredibly complex challenge. In fact, many considered it impossible. But thanks to cutting-edge research and programs, the ability to restore vision is getting closer than ever. As a first for this podcast, this episode features an interview with Dr. Cal Roberts himself! Adapting audio from an interview on The Doctors Podcast, Dr. Cal describes his work as a program manager for a project on eye transplantation called Transplantation of Human Eye Allographs (THEA). Funded by a government initiative called ARPA-H, THEA is bringing some of the country's finest minds together to tackle the complexities of connecting a person's brain to an eye from a human donor. This episode also features an interview with Dr. Daniel Palanker of Stanford University. Dr. Palanker is working on technology that can artificially restore sight through prosthetic replacement of photoreceptors. Having proved successful in animals, Dr. Palanker and his team are working hard to translate it to humans. And if that can happen, then something once considered impossible could finally be accomplished!   The Big Takeaways The Challenges of Eye Transplants: Although eyeball transplants have been done, they've only been cosmetic. So far, nobody has been able to successfully connect a donor eyeball to a recipient's brain. Dr. Roberts's work with THEA is bringing together multiple teams to tackle the challenges associated with a whole eyeball transplant, from connecting nerves and muscles to ensuring the organ isn't rejected, and much more. “Artificial” Vision Restoration: Dr. Palanker is working to replace the functions of photoreceptors through technological means. His photovoltaic array is placed underneath the retina and can convert light into an electrical current that activates the cells that send visual information to the brain. While it doesn't completely restore sight for people with Age-Related Macular Degeneration, this technology shows incredible promise. Decoding “Brain Language”: For both Dr. Roberts and Dr. Palanker, one of the biggest challenges with vision restoration is understanding how the eye and brain communicate. Dr. Roberts likens it to Morse Code — the eye speaks to the brain in “dots and dashes,” which the brain then converts into vision. Right now, the language is still foreign to us, but we're closer than ever to decoding it. The Evolution of the Brain-Machine Interface: Dr. Palanker imagines incredible possibilities in the interaction between the brain and technology. If we can find a way to truly translate the brain's signals into information, Dr. Palanker envisions the possibility of direct brain-to-brain communication without verbalization. In a way, this could make people telepathic, able to understand and digest vast amounts of information in an instant.   Tweetables: So ideally in medicine, at least the ideal therapy is the restoration of full functionality. If we can grow back photoreceptors and make them reconnect to bipolar cells, undo all the rewiring that right now underwent during degeneration, and restore the full extent of vision, that would be the ideal outcome. — Dr. Daniel Palanker, Professor of Ophthalmology, Stanford University We can think about other aspects of brain-machine interface, which takes you maybe into the realm of capabilities that humans never had. If you enable artificial senses or enable brain-to-brain connectivity so you can communicate without verbalization that would open completely new capabilities that humanity never had. — Dr. Palanker Forty-two years after the implantation of the first mechanical heart, there's not a single person in the world walking around with a mechanical heart. All that work, all that research, and all that effort to come up with mechanical heart transplants are still state-of-the-art. And so, while I believe that there is a role for a bionic eye or mechanical eye, what I really believe is that everything that we learn from doing an eye transplant will just make it better and easier when we do eventually come up with a bionic or a mechanical eye. — Dr. Calvin Roberts, ARPA-H Health Science Futures Program Manager (President and CEO of Lighthouse Guild and Host of On Tech & Vision!)   Contact Us: Contact us at podcasts@lighthouseguild.org with your innovative new technology ideas for people with vision loss.   Pertinent Links Lighthouse Guild THEA Program Prima System   People's Choice Podcast Awards We appreciate your support for our show — and now, we need your help nominating the On Tech & Vision podcast for the People's Choice Podcast Awards! We are participating in these awards so we can showcase On Tech & Vision to a broader audience, gain recognition within the industry, and, most importantly, help spread the message about Lighthouse Guild and the role that technology is playing in tearing down barriers for people who are blind or visually impaired. To help us nominate On Tech & Vision, please go online to www.podcastawards.com, where you can register to vote for On Tech & Vision in both the Technology and Peoples' Choice Categories. Voting is open until July 31st. Once again, your support is greatly appreciated!

Host Robert Traynham is joined by Dr. Bon Ku of the Advanced Research Projects Agency for Health (ARPA-H), a new federal agency aimed at pioneering ambitious health care initiatives. Dr. Ku will talk about the PARADIGM program, rural health care, and the concept of health care design.

Director of ARPA-H, Dr. Renee Wegrzyn, joins host Jeanne Meserve for a live conversation to discuss the agency's role in investing in new and critical technologies at SCSP's AI Expo. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit scsp222.substack.com

Reid Hoffman, co-Founder of LinkedIn and Inflection AI discusses the possibilities and risks that artificial intelligence will pose over the next decade and why he believes everyone will have an AI digital agent in the future. Then, ARPA-H director, Renee Wegrzyn and MIT School of Engineering Professor of AI and Health discuss how AI is changing the health-care landscape and what the industry can do right now to implement the technology into its infrastructure. Conversation recorded on June 13, 2024 at The Futurist: The Age of AI summit.

Ever wondered how to navigate the complexities of data classification within your organization? Get ready to sharpen your cybersecurity skills and elevate your knowledge as we dissect CISSP Question Thursday, focusing on domain 2.1.1. This week, we also bring you an intriguing piece of news about ARPA-H, a groundbreaking new agency inspired by DARPA but aimed at revolutionizing healthcare through cutting-edge technology. With a starting fund of $50 million, ARPA-H is set to tackle critical issues like ransomware in the healthcare sector, presenting immense opportunities for those in the cybersecurity field.We go beyond the basics as we cover crucial aspects of data classification and security protocols across diverse organizational contexts. Learn how to classify different types of data, from marketing campaign materials to sensitive patient information, and understand why encryption is essential for protecting data at rest. We also discuss the limitations of Data Loss Prevention (DLP) solutions and offer key security considerations for managing user geolocation data in mobile apps. This episode is a must-listen for anyone preparing for the CISSP exam or looking to enhance their cybersecurity expertise.Gain access to 30 FREE CISSP Exam Questions each and every month by going to FreeCISSPQuestions.com and sign-up to join the team for Free. Gain access to 60 FREE CISSP Practice Questions each and every month for the next 6 months by going to FreeCISSPQuestions.com and sign-up to join the team for Free. That is 360 FREE questions to help you study and pass the CISSP Certification. Join Today!

In this thought-provoking session, we will delve into the recent surge of attention and investment in women's health. From President Biden's groundbreaking Executive Order to the ambitious ARPA-H Sprint, and even celebrity advocacy, the landscape of women's health is undergoing a significant transformation. Join us for an insightful discussion as we navigate the evolving landscape of women's health. We explore how health IT leaders can capitalize on this unprecedented attention to drive meaningful advancements in care delivery, research, and innovation. Together, we will assess whether women's health is finally receiving the attention and investment it deserves and chart a course for a more equitable and empowering future. As health IT leaders, it is crucial to understand how these developments will impact our strategies, investments, and the overall direction of the industry. We will explore the following key aspects:State of Innovation in Women's HealthFrom Mensus to Menopause Who Pays and Why? Identifying key areas of opportunity for health IT investments, partnerships, and collaborations that align with the current focus on women's health and strategies to optimize resource allocation and maximize impactBiden's Executive Order: Analyzing the implications of the President's directive on women's health and how it will shape policies, funding, and priorities in the healthcare sector.Accelerating innovation through a $100 million ARPA-H women's health sprint- discussing how this initiative could accelerate innovation and drive meaningful change.Assessing the impact of high-profile figures like Oprah in raising awareness and mobilizing resources for women's health causes, and exploring how health IT leaders can leverage this momentum to drive positive outcomes. Katie McMillan, CEO, Well Made Health, LLCMegan Antonelli, Chief Executive, Officer HealthIMPACT

April 8, 2024: David Ting, Founder and CTO at Tausight joins Drex DeFord, President, 229 Risk & Security at This Week Health for the news. As we delve into the conversation, Ting shares his insights on the challenges and opportunities presented by the current state of cybersecurity in healthcare, particularly in light of recent high-profile cyber events. How will increased regulations and mandates impact healthcare organizations, and is there a balance to be struck between compliance and genuine security? Ting also explores the hyperconnected nature of healthcare and the vulnerabilities it introduces. Could the solution lie in not just more regulations but in providing healthcare organizations with the necessary incentives and financial assistance to bolster their cybersecurity measures? Furthermore, we touch upon the potential of AI in revolutionizing healthcare cybersecurity, as highlighted by the partnership between ARPA H and DARPA.Key Points:Impact of Increased RegulationsFinancial Assistance and IncentivesSecuring Pediatric Health DataPartnership Between ARPA H and DARPANews articles:Processing Mismanagement: Responding to Change Healthcare's Meltdown - 4sight HealthDear Colleague Letter2 Minute Drill: Budget Dust and Cyber Urgency: A Call for Stronger Hospital SecurityRansomware attack on Change Healthcare pegged as "most significant" in sector historyThis Week Health SubscribeThis Week Health TwitterThis Week Health LinkedinAlex's Lemonade Stand: Foundation for Childhood Cancer Donate

Dr. Darshak Sanghavi, MD ( https://arpa-h.gov/about/people/darshak-sanghavi ) is Program Manager, Resilient Systems Mission Office, at ARPA-H where he heads up the HEalthcare Rewards to Achieve Improved OutcomES ( HEROES - https://arpa-h.gov/research-and-funding/programs/heroes ) program which aims to trial and validate radically different approaches to creating preventative care incentives in the health market, one example being offering direct payments to individual “health accelerators” – such as non-profits or care consortiums – that successfully implement preventative care campaigns that improve the rates for specific health harms in an entire geographic population. Dr. Sanghavi joined ARPA-H in May 2023 from Babylon – a digital-first, end-to-end health care provider serving more than 24 million people across the globe. As chief medical officer, he was responsible for overseeing the company's international operations as well as leading its wider mission to help bring affordable and accessible health care to everyone worldwide. Previously, Dr. Sanghavi worked as national chief medical officer for UnitedHealthcare and OptumLabs, as a group director at the Centers for Medicare & Medicaid Services Innovation Center during the Obama Administration, as managing director of the Engelberg Center for Health Care Reform at the Brookings Institute, and as a pediatrician for the U.S. Indian Health Service. Dr. Sanghavi has a doctorate in medicine from Johns Hopkins University and specializes in pediatric cardiology after training at Boston Children's Hospital. Dr. Sanghavi is also a best-selling author, with his book "A Map of the Child: A Pediatrician's Tour of the Body", available at all major book sellers, and a regular contributor to the New York Times, Boston Globe, and Washington Post. Support the show

This week on StartUp Health NOW, we have again handed over the microphones to two members of our Health Moonshot Impact Board and having them interview each other. At one end of the table we've got Margaret Laws, CEO & President of HopeLab, former Director of Innovations for the Underserved at CHCF, and Founder of the CHCF Health Innovation Fund, and at the other end of the interview table is Shirley Bergin, Senior Advisor at ARPA-H, Former CMO/COO of TEDMED, and Advisor to Ellipsis Health and Cure. The goal of the conversation was simply to hear about the latest projects and passions of two of the most influential and interesting people in health innovation. In the interview, which took place in person at the Lake Nona Impact Forum in Florida, we cover a range of topics, from youth mental health, to the role of AI in diagnostics, to education to address global gaps in the healthcare workforce. Margaret Laws and Shirley Bergin are thought leaders in health innovation, but they're also deeply involved in directing funds towards promising programs, so it will be interesting to see how their curiosities and passions as played out here will lead to concrete moves in the future. Enjoy the conversation. Innovating in Alzheimer's disease? Learn how you can join our new Alzheimer's Moonshot. Passionate about Type 1 diabetes? Learn how you can get one of the last spots in our T1D Moonshot. Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox. Innovators: Health Transformer University fuels your health moonshot Funders: Become a Health Moonshot Champion

President Biden has announced a comprehensive initiative, including a new executive order aimed at revolutionizing women's health research and innovation across America. Rooted in his State of the Union vision, Biden has proposed a transformative $12 billion investment to establish a fund for Women's Health Research at NIH. This initiative, the first White House initiative on women's health research, seeks to fundamentally alter the landscape of women's health research in the U.S. and ensure comprehensive integration and prioritization within the federal research agenda. It encompasses a broad spectrum of actions, including a $200 million NIH investment for the 2025 fiscal year and the launch of ARPA-H's Sprint for Women's Health with a $100 million commitment. The initiative's directives include enhancing research across various stages of women's lives, particularly focusing on midlife health challenges and leveraging AI in health research advancements. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Calvin Roberts, M.D. is Program Manager at the Advanced Research Projects Agency for Health (ARPA-H) where manages for the Transplantation of Human Eye Allografts ( THEA - https://arpa-h.gov/research-and-funding/programs/thea ) program, which aims to transplant whole human eyes to restore vision in patients who are blind or visually impaired by reconnecting the nerves, muscles and blood vessels of whole donor eyes to the brain. Dr. Roberts joined ARPA-H in September 2023 from Lighthouse Guild International, where is the president and chief executive officer. Lighthouse Guild is a not-for-profit organization that provides programs and services to people who are blind or visually impaired. Previously, Dr. Roberts was the chief medical officer for the global eye care company Bausch + Lomb. For the past 40 years, Roberts has also served as a clinical professor of ophthalmology at Weill Cornell Medical Center. As a practicing ophthalmologist from 1982 to 2008, he performed more than 10,000 cataract surgeries, as well as 5,000 refractive and other corneal surgeries. He is credited with developing surgical therapies, over-the-counter products for vision care, prescription ocular therapeutics and innovative treatment regimens. He also holds patents on the wide-field specular microscope and has done extensive research on ophthalmic non-steroidals and post-operative cystoid macular edema. Dr. Roberts also hosts the podcast series “On Tech and Vision” ( https://lighthouseguild.org/technology/on-tech-and-vision-podcast/ ) – where innovators discuss how rapidly evolving assistive technology creates equity among those who are visually impaired. Dr. Roberts received his medical degree from Columbia University, completed an internship and ophthalmology residency at New York Presbyterian Hospital, and conducted cornea fellowships at Massachusetts Eye and Infirmary and the Schepens Eye Institute. Support the show

This week, we're super excited to chat with Brian Anderson, co-founder of CHAI, Coalition for Health AI, and Chief Digital Health Physician at MITRE. CHAI is a community of academic health systems, organizations, and expert practitioners of artificial intelligence and data science. Brian leads research and development efforts across major strategic initiatives in digital health, partnering with the US government and private sector companies.  Prior to joining MITRE, Anderson led the Informatics and Network Medicine Division at athenahealth, where he launched a new model of clinical decision support leveraging artificial intelligence. He has also served on several national health information technology committees in partnership with the Office of the National Coordinator (ONC). On top of all that, Brian is also a Harvard Medical School Associate Professor of Biomedical Informatics and senior advisor for ARPA-H in Clinical Trial Innovation. Anderson completed his clinical training at Massachusetts General Hospital and completed his B.A. and M.D. degrees at Harvard College and Harvard Medical School. In this episode, we talk about Brian's career journey from clinical practice to digital health, CHAI's efforts to establish AI process standards for healthcare, the concept of a federated network of assurance labs, and advice for the health AI innovation community. 

Quick episode summary John A. Hovanesian, MD, FACS, and Jim Mazzo sit down with guests Eric D. Donnenfeld, MD, Calvin C. Roberts, MD, Mark L. Baum and Jeannette Bankes to discuss private equity, industry breakthroughs and more. Welcome to the Eyeluminaries podcast :00 Review of episode 20 1:16 Intro of Eric D. Donnenfeld, MD 2:06 Understanding the role of private equity: where does it stand and where is it going? 4:22 Do you see a relief in interest rates and the pace picking up for private equity in the years ahead? 7:19 What are the technologies that you are most excited about? 8:17 What are the things to watch out for? 11:08 Do you have an interesting James Worthy story? 13:34 Intro of Calvin C. Roberts, MD 15:21 Transplanting eyes and Advanced Research Project Agency for Health (ARPA-H) 15:48 How does a chief medical officer work within a company? 18:56 How is what ARPA-H doing different than simply transplanting an eye? 20:42 Intro of Mark L. Baum 26:06 What does the rebranding of the company mean? 27:00 Pharmaceutical names: VEVYE 28:22 How will you market VEVYE in the US? 29:48 Fortisite 31:59 What is the future of the company? 32:47 What do you think of Dr. Wiley Chambers' retirement? 34:09 Intro of Jeannette Bankes 36:51 Describe your last five years in the ophthalmic space: the good, the bad, the ugly 39:16 ·       If you could change anything in the ophthalmic industry, what would it be? 42:53 ·       How excited are you about robotics? 44:06 ·       Tell us about your promotion 44:52 ·       How can we develop a more diverse leadership in ophthalmology? 45:31 Preview of episode 22 48:01 Feedback, questions and guest suggestions at eyeluminaries@healio.com 48:18   Jeannette Bankes is the president and general manager of global surgical franchises for Alcon. Mark L. Baum is the founder, chairman of the board and chief executive officer of Harrow. Eric D. Donnenfeld, MD, is a cornea, laser cataract and refractive surgeon for OCLI Vision. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Calvin C. Roberts, MD, is a program manager for health science futures at ARPA-H. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Bankes is the president and general manager of global surgical franchises for Alcon. Baum is the founder, chairman of the board and chief executive officer of Harrow. Donnenfeld reports consulting widely across the ophthalmic industry with relevant disclosures in this episode as a consultant with Alcon, Bausch + Lomb, LensGen, Ocular Therapeutix and Omeros. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Thompson is the director of refractive surgery at Vance Thompson Vision. Roberts is program manager for health science futures at ARPA-H.

Welcome to the daily304 – your window into Wonderful, Almost Heaven, West Virginia.   Today is Friday. Feb. 2  Looking for a good-paying and rewarding job? WV corrections facilities are hiring. Two WV chefs are semifinalists for the prestigious James Beard award. And WVU enters a new research partnership that may spark health innovation…on today's daily304. #1 – From JOBCASE – Explore a stable and rewarding career with the West Virginia Division of Corrections and Rehabilitation. As a correctional officer, you'll play a pivotal role in ensuring public safety, upholding public trust and contributing to a higher purpose. You'll be making a real impact on your community.  Higher salaries await you, starting at a minimum of $40,000 annually plus a retention bonus after one year and further salary increases after two years. You'll also receive a great benefits package and paid leave. Additional perks include paid training and plenty of advancement opportunities. What are you waiting for? Visit www.jobcase.com/ru/West-Virginia to find out who's hiring! Read more: https://www.jobcase.com/articles/wv-dcr   #2 – From WCHS-TV – Two chefs from West Virginia have been recognized for culinary excellence with James Beard Award nominations. Chef Paul Smith, of 1010 Bridge in Charleston, has been nominated for best chef of the southeast while Scott MacGregor, from Snowshoe's Appalachian Kitchen, joins the semifinalist list. “It's a huge deal,” said Smith, who was one of five finalists last year. “I wouldn't say it's a dream come true because it's beyond our wildest dreams. This is the Academy Awards for chefs, so just to be nominated you are an Academy Award-winning chef basically." “It was shocking. It was definitely exciting,” MacGregor said. “It was an honor for me to think that I'm in there with people from huge food cities, like Memphis, Nashville, Charleston, South Carolina and all of these places that are kind these up-and-running food cities. I'm here in the middle of the mountains.” Finalists will be announced in March. Read more: https://wchstv.com/news/local/two-wva-chefs-nominated-for-coveted-james-beard-awards-appalachian-kitchen-scott-macgregor-1010-bridge-paul-smith-snowshoe-charleston-culinary-west-virginia   #3 – From WVU TODAY – West Virginia University has been tapped to help accelerate commercialization of medical innovations by collaborating with a nationwide network within the National Institutes of Health. WVU is one of just 127 entities to be named a spokesmember or partner for the Investor Catalyst Hub, a regional hub of the Advanced Research Projects Agency for Health. The University is the only member from West Virginia. ARPA-H's overarching mission is to improve health outcomes through the following research focus areas: health science futures, proactive health, scalable solutions and resilient systems. As a member of the hub, WVU will have access to potential funding and flexible contracting for faster award execution compared to traditional government contracts. “We will be able to tap into a wealth of knowledge and expertise that is represented through the spokes and are excited for the possibilities that will emerge from the ARPA-H partnerships,” said Erienne Olesh, executive director of the Office of Student and Faculty Innovation in the WVU Research Office.   Read more: https://wvutoday.wvu.edu/stories/2024/01/29/wvu-selected-to-partner-with-federal-research-entity-to-spark-health-innovation   Find these stories and more at wv.gov/daily304. The daily304 curated news and information is brought to you by the West Virginia Department of Commerce: Sharing the wealth, beauty and opportunity in West Virginia with the world. Follow the daily304 on Facebook, Twitter and Instagram @daily304. Or find us online at wv.gov and just click the daily304 logo.  That's all for now. Take care. Be safe. Get outside and enjoy all the opportunity West Virginia has to offer.

Government is typically not one to take risks, but Advanced Research Projects Agency for Health (ARPA-H) CIO Nikolaos Ipiotis said failing and learning are key parts to tech and health innovation. The agency, the newest one within the National Institutes of Health, aims to transform and innovate in health IT, medicine and other lanes of research that aren't easily available through traditional approaches. Ipiotis, who joined the agency in December 2023, said in his first podcast interview that taking risks, "controlled failure" and collaboration are all keys to his IT strategy. He discusses what lies ahead for data strategy as the agency begins to collaborate with industry and set in motion major initiatives for the health community.

Texas is a large state with a huge population to take care of. With recent moves to provide better healthcare, Texas is said to be the leading state for advancing healthcare and medical education. Recently, ARPA-H, a medical innovation federal agency, has declared Dallas as one of its three national hub spaces for its medical breakthroughs in science and medicine. So, Texas wants to know, what is ARPA-H and what the hub here means for our state and Texans?

Contact Me Here - ❤️ https://bit.ly/m/TammyCuthbertGarcia ❤️   Today on Naturally Inspired Radio lifestyle activities, Dr Joseph Ladapo sends letter to FDA and CDC, pharmacies giant paid 25.8 million dollars to obesity specialists to sell weight loss drugs, anti human cult is after a cure for death, ARPA-H supported by the Biden administration, arthritis solutions, leaky gut, allergies, MSM, healing properties of laughter      Tune In to Naturally Inspired Radio Live… Mon-Thu, 3pm (MDT) on 1360am KHNC in Colorado, at https://bit.ly/naturallyinspiredradio   Text in your comments/questions to 877-536-1360 and enter to win our weekly giveaway   Please Like

The Advanced Research Projects Agency for Health is embracing generative artificial intelligence as part of its internal operations, while also considering how the technology could be used across the broader health ecosystem.Launched in March 2022, ARPA-H is an independent agency within the National Institutes of Health. The organization is modeled after the Defense Advanced Research Projects Agency, with the goal of supporting “transformative research to drive biomedical and health breakthroughs.”Susan Monarez, deputy director at ARPA-H, said officials are already using generative AI technologies to help the new research organization “get our houses in order.” She said the agency processes large volumes of data ranging from personnel information to contracting data to information from partner agencies that help ARPA-H shape its programs. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Advanced Research Projects Agency for Health is embracing generative artificial intelligence as part of its internal operations, while also considering how the technology could be used across the broader health ecosystem. Launched in March 2022, ARPA-H is an independent agency within the National Institutes of Health. The organization is modeled after the Defense Advanced Research Projects Agency, with the goal of supporting “transformative research to drive biomedical and health breakthroughs.” Susan Monarez, deputy director at ARPA-H, said officials are already using generative AI technologies to help the new research organization “get our houses in order.” She said the agency processes large volumes of data ranging from personnel information to contracting data to information from partner agencies that help ARPA-H shape its programs. Learn more about your ad choices. Visit megaphone.fm/adchoices

In September 2023, Mathematica and Congressman Don Beyer's office hosted an event on Capitol Hill to discuss artificial intelligence (AI) and its implications for health equity. This episode of On the Evidence features audio from the September event, anchored by Victoria Knight, a health care policy reporter for Axios, who interviewed Congressman Beyer and moderated a subsequent panel with Ellie Graeden, Jen Roberts, Ngan MacDonald, and Deliya Wesley. • Beyer represents the 8th Congressional District of Virginia and is a vice chair of both the bipartisan Congressional AI Caucus and an AI working group recently formed by the New Democrat Coalition. • Graeden is a professor at the Georgetown University Center for Global Health Science and Security. • Roberts is a director of resilient systems at the Advanced Research Projects Agency for Health, also known as ARPA-H. • MacDonald is the chief of data operations for the Institute for AI in Medicine at Northwestern University. • Wesley is a senior director of health equity at Mathematica. Learn more about how Mathematica's experts harness vast data, advanced analytics, and deep health care policy experience to help organizations make sense of real-world data in a way that enables exploration and innovation: https://mathematica.org/sp/data-analytics/real-world-data Find a transcript of the episode at mathematica.org/blogs/how-artificial-intelligence-can-advance-health-equity

The Advanced Research Projects Agency for Health has proceeded with its promised network of health innovation sites. Anchoring the network are three regional hubs also planned at the inception of ARPA-H. For what they hope for the network, Federal Drive Host Tom Temin talked with the Director of the agency's Project Accelerator Transition Innovation office, Craig Gravitz. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Advanced Research Projects Agency for Health has proceeded with its promised network of health innovation sites. Anchoring the network are three regional hubs also planned at the inception of ARPA-H. For what they hope for the network, Federal Drive Host Tom Temin talked with the Director of the agency's Project Accelerator Transition Innovation office, Craig Gravitz. Learn more about your ad choices. Visit megaphone.fm/adchoices

Emerging technologies are poised to greatly impact federal agencies. In health care and health research, this is unlocking tremendous opportunity for researchers advancing treatments, diagnostics and more. The National Center for Advancing Translational Sciences's five-year plan outlines how AI and machine learning will address big data and translational barriers. This plan aims to bridge the gap between scientific and operational challenges by improving engagement in the translational space as well as serve as a guide to other agencies when it comes to preparing for future health emergencies like COVID-19. NCAYS Branch Chief of the Office of Policy, Communications and Education Dr. Meredith Temple O'Connor briefs us on this plan plus the expansion of the N3C program comprising COVID clinical data, how AI is shortening the diagnostic odyssey for rare diseases and what's going on with its new partnership with ARPA-H.

Pink Sheet reporters and editor discuss the problems that emerged for the US FDA from just the threat of a government shutdown (:38), take-aways on the FDA advisory committee process based on the complete response letter issued for Alnylam's Onpattro (10:25), and incentives that the FDA could offer for ARPA-H projects that reach the application stage (20:16). More On These Topics From The Pink Sheet Shutdown Threat Forced US FDA To Cancel Some Travel: https://pink.citeline.com/PS149003/Shutdown-Threat-Forced-US-FDA-To-Cancel-Some-Travel Alnylam's Complete Response Is Classic Example Of FDA-Advisory Committee Disagreement: https://pink.citeline.com/PS149000/Alnylams-Complete-Response-Is-Classic-Example-Of-FDA-Advisory-Committee-Disagreement US FDA Rejects Onpattro Label Expansion: History Repeats In Reverse?: https://pink.citeline.com/PS149004/US-FDA-Rejects-Onpattro-Label-Expansion-History-Repeats-In-Reverse ARPA-H, US FDA Discuss Incentives For Game-Changing Health Projects: https://pink.citeline.com/PS148944/ARPAH-US-FDA-Discuss-Incentives-For-GameChanging-Health-Projects

Dr. Renee Wegrzyn is the first director of the Advanced Research Projects Agency for Health, (ARPA-H), a new federal agency with a $2.5 billion budget. Modeled after DARPA, the agency is tasked with taking big risks in biomedical research that seem beyond the reach of the private sector. Dr. Wegrzyn joins Preet to discuss how ARPA-H is promoting innovation, and their goal to “end cancer as we know it.”  Stay Tuned is nominated for a Signal Award…and you're in the jury box! Head to cafe.com/signal to vote.  Stay Tuned in Brief is presented by CAFE and the Vox Media Podcast Network. Please write to us with your thoughts and questions at letters@cafe.com, or leave a voicemail at 669-247-7338. For analysis of recent legal news, join the CAFE Insider community. Head to cafe.com/insider to join for just $1 for the first month.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here's what you need to know for today, September 28, 2023. Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast. QT Medical this week announced it raised $12 million in a Series B funding round. Fast Five hosts Sean Whooley and Danielle Kirsh explain what that technology is and how optimistic executives are feeling after the funding round.  BCIs are in the news again this week.  This time, Onward announced the first-in-human implant of a stimulator with BCI technology. Whooley details how the technology works with the BCI and what doctors think after the first implant.  Boston Scientific won an FDA nod for its intravascular ultrasound system. Hear how the system works and how it assists clinicians, as well as some of the features that help support clinicians.  The NIH this week chose Boston as its location for its ARPA-H Catalyst Hub. The Fast Five hosts discuss the details behind this NIH initiative and what organizations will be a part of the hub.  Edwards Lifesciences was revealed as the mystery company facing antitrust scrutiny in Europe, first announced last week. Find out what Edwards' response was to the antitrust investigation.

Imagine a federal procurement shop where you use every technique, except the Federal Acquisition Regulation. And you don't do grants, either. And you've got congressional backing for your novel approach. That's the case for one of the government's newer agencies, the Advanced Research Projects Agency for Health, known as ARPA-H. For a look on the inside, Federal Drive Host Tom Temin spoke with Diane Sidebottom, ARPA-H Director of Acquisition and Contracts. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Imagine a federal procurement shop where you use every technique, except the Federal Acquisition Regulation. And you don't do grants, either. And you've got congressional backing for your novel approach. That's the case for one of the government's newer agencies, the Advanced Research Projects Agency for Health, known as ARPA-H. For a look on the inside, Federal Drive Host Tom Temin spoke with Diane Sidebottom, ARPA-H Director of Acquisition and Contracts. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Rebecca Schaefer and Martin Folliard discuss cybersecurity threats faced by health care organizations and a new federal research agency initiative to help create security tools to protect the US health care system from cyberattacks.

On location at Aspen Ideas-Health, hosts Mark Masselli and Margaret Flinter talking with the leaders of a new innovation effort. Advanced Research Projects Agency for Health (ARPA-H) is backed by $2.5 billion dollars in federal money with a mandate to accelerate better health outcomes for everyone. The initiative aims to work outside of traditions with a “range of performers and a variety of approaches to solve” health care's biggest hurdles. Can they find a way to reduce cancer deaths? That's one of the questions Masselli and Flinter ask Renee Wegrzyn, ARPA-H's director and Amy Jenkins, its director of Health Science Futures. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

In this episode of Storm Watch, the hosts discuss their experiences at Hacker Summer Camp and their excitement about new sensors they've been working with. They consider the possibility of doing a demo in the next episode and mention some sneak peeks available on Andrew's Twitter account. The conversation then shifts to the extreme weather conditions they've been experiencing, including heat domes and "her quakes." The hosts express their disappointment with the lack of progress made by federal departments and agencies in response to the Biden-Harris administration's executive order on cybersecurity. They emphasize the importance of faster reporting and applying basic cybersecurity principles. They also discuss the massive number of victims affected by the "Move It" ransomware, urging cybersecurity professionals to focus on healthcare and other underserved areas. The ARPA-H initiative, or "DigiHeals," is introduced as a government research project aimed at improving healthcare cybersecurity. The hosts share their concerns about the vulnerabilities they've observed in healthcare networks and encourage cybersecurity professionals to dedicate time to helping these critical systems. They also announce the winners of the first annual inaugural Noise Fest CTF of 2023, a Capture the Flag competition organized by the GreyNoise Labs team. Learn more about GreyNoise >>

From its beginnings in 1958 as the Advanced Research Projects Agency to the eventual folding into the Department of Defense in 1972 under its current acronym, DARPA has always been on the cutting edge of technological advancements in the fields of aerospace, defense, computing, and intelligence gathering. These days DARPA is best known for scary robot dogs and brain implants, but the United States government has big plans for expanding the concept of advanced research with “High-risk, High-reward” expectations into the health industry with the creation of ARPA-H in 2022 to take the medical industry where DARPA took the defense contractors. Prepare to be terrified of where this technology is headed and who ultimately has control over its usage, because the robot dogs of your nightmares are only the beginning. Freeworld NYC 9/11 Live Event Tickets: https://www.eventbrite.com/e/free-world-nyc-tickets-667727369537 American Liberty Awards: www.americanlibertyawards.com Christian Yordanov's Detoxification Program: https://members.christianyordanov.com/detox-workshop?coupon=MACRO Sponsors: Emergency Preparedness Food: www.preparewithmacroaggressions.com Chemical Free Body: https://www.chemicalfreebody.com Promo Code: MACRO C60 Purple Power: https://c60purplepower.com/ Promo Code: MACRO Wise Wolf Gold & Silver: www.Macroaggressions.gold True Hemp Science: https://truehempscience.com/ Haelan: https://haelan951.com/pages/macro Solar Power Lifestyle: https://solarpowerlifestyle.com/ Promo Code: MACRO LegalShield: www.DontGetPushedAround.com EMP Shield: www.EMPShield.com Promo Code: MACRO Coin Bit App: https://coinbitsapp.com/?ref=0SPP0gjuI68PjGU89wUv Macroaggressions Merch Store: https://www.teepublic.com/stores/macroaggressions?ref_id=22530 LinkTree: linktr.ee/macroaggressions Books: HYPOCRAZY: https://amzn.to/3VsPDp8 Controlled Demolition on Amazon: https://amzn.to/3ufZdzx The Octopus Of Global Control: Amazon: https://amzn.to/3VDWQ5c Barnes & Noble: https://bit.ly/39vdKeQ Online Connection: Link Tree: https://linktr.ee/Macroaggressions Instagram: https://www.instagram.com/macroaggressions_podcast/ Discord Link:  https://discord.gg/4mGzmcFexg Website: www.theoctopusofglobalcontrol.com Facebook: www.facebook.com/theoctopusofglobalcontrol Twitter: www.twitter.com/macroaggressio3 Twitter Handle: @macroaggressio3 YouTube: www.youtube.com/channel/UCn3

We're on location at Aspen Ideas-Health, talking with the leaders of a new innovation effort. Advanced Research Projects Agency for Health (ARPA-H) is backed by $2.5 billion dollars in federal money with a mandate to accelerate better health outcomes for everyone. The initiative aims to work outside of traditions with a “range of performers and a variety of approaches to solve” health care's biggest hurdles. Can they find a way to reduce cancer deaths? That's one of the questions hosts Mark Masselli and Margaret Flinter ask Renee Wegrzyn, ARPA-H's director and Amy Jenkins, its director of Health Science Futures.

We're on location at Aspen Ideas-Health, talking with the leaders of a new innovation effort. Advanced Research Projects Agency for Health (ARPA-H) is backed by $2.5 billion dollars in federal money with a mandate to accelerate better health outcomes for everyone. The initiative aims to work outside of traditions with a “range of performers and a variety of approaches to solve” health care's biggest hurdles. Can they find a way to reduce cancer deaths? That's one of the questions hosts Mark Masselli and Margaret Flinter ask Renee Wegrzyn, ARPA-H's director and Amy Jenkins, its director of Health Science Futures. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Ross Uhrich, DMD, MBA, is Program Manager, Advanced Research Projects Agency for Health ( ARPA-H - https://arpa-h.gov/people/ross-uhrich/ ), which is focused on advancing high-potential, high-impact biomedical and health research that cannot be readily accomplished through traditional research or commercial activity, accelerating better health outcomes targeting society's most challenging health problems. Under the ARPA-H portfolio, Dr. Uhrich is responsible for the recently launched Novel Innovations for Tissue Regeneration in Osteoarthritis ( NITRO - https://arpa-h.gov/engage/programs/nitro/ ) program which seeks to develop new ways of helping the human body repair its own joints, with the goal of revolutionizing treatment for osteoarthritis — a common and often very painful condition where bones and cartilage break down. Dr. Uhrich joined ARPA-H in March 2023 from Walter Reed National Military Medical Center (WRNMMC) and the Uniformed Services University of the Health Sciences, where he worked as a board-certified oral and maxillofacial surgeon and assistant professor of surgery. In addition to these roles, he spent 12 years with the U.S. Navy, finishing his tenure as a Lieutenant Commander. Throughout his career, Dr. Uhrich has cared for thousands of members of the U.S. Armed Forces at various healthcare facilities, including the USS Gerald R. Ford , Naval Health Clinic Quantico, and WRNMMC, and served as an oral and maxillofacial surgery consultant to Congress. He also treated patients at Charleston Area Medical Center, R Adams Cowley Shock Trauma Center, and Suburban Hospital. Dr. Uhrich holds a doctorate in dental medicine from the University of Pennsylvania, an MBA from the University of Virginia, and completed his surgical residency at WRNMMC. He also has a Bachelor of Science in Biomedical Engineering from Yale University. Support the show

In today's podcast episode, I talk with Renee Wegrzyn,  appointed by President Biden as the first director of a federal agency created last year called the Advanced Research Projects Agency for Health, or ARPA-H. It's inspired by DARPA, the agency that develops innovations for the Defense department and has been credited with hatching world changing technologies such as ARPANET, which became the internet.Time will tell if ARPA-H will lead to similar achievements in the realm of health. That's what President Biden and Congress expect in return for funding ARPA-H at 2.5 billion dollars over three years. How will the agency figure out which projects to take on, especially with so many patient advocates for different diseases demanding moonshot funding for rapid progress. I talked with Dr. Wegrzyn about the opportunities and challenges, what lessons ARPA-H is borrowing from Operation Warp Speed, how she decided on the first ARPA-H project which was just announced recently, why a separate agency was needed instead of trying to reform HHS and the National Institutes of Health to be better at innovation, and how ARPA-H will make progress on disease prevention in addition to treatments for cancer, Alzheimer's and diabetes, among many other health priorities.Dr. Wegrzyn's resume is filled with experience for her important role. She was a program manager at DARPA where she focused on applying gene editing and synthetic biology to the goal of improving biosecurity. For her work there, she was given the Superior Public Service Medal and, just in case that wasn't enough ARPA experience, she also worked at another ARPA that leads advanced projects in intelligence, called I-ARPA. Before that, she was in charge of technical teams in the private sector working on gene therapies and disease diagnostics, among other areas. She has been a vice president of business development at Gingko Bioworks and headed innovation at Concentric by Gingko. Her training and education includes a PhD and undergraduate degree in applied biology from the Georgia Institute of Technology and she did her postdoc as an Alexander von Humboldt Fellow in Heidelberg, Germany.As Dr. Wegrzyn told me, she's “in the hot seat” - the pressure is on for ARPA-H especially after the need and potential for health innovation was spot lit by the pandemic and the unprecedented speed of vaccine development. We'll soon find out if ARPA-H can produce something in health that's equivalent to DARPA's creation of the internet.Show links:ARPA-H - https://arpa-h.gov/Dr. Wegrzyn profile - https://arpa-h.gov/people/renee-wegrzyn/Dr. Wegrzyn Twitter - https://twitter.com/rwegrzyn?lang=enPresident Biden Announces Dr. Wegrzyn's appointment - https://www.whitehouse.gov/briefing-room/statements-releases/2022/09/12/president-biden-announces-intent-to-appoint-dr-renee-wegrzyn-as-inaugural-director-of-advanced-research-projects-agency-for-health-arpa-h/Leaps.org coverage of ARPA-H - https://leaps.org/arpa/ARPA-H program for joints to heal themselves - https://arpa-h.gov/news/nitro/ - ARPA-H virtual talent search - https://arpa-h.gov/news/aco-talent-search/Leaps.org is a not-for-profit initiative that publishes award-winning journalism, popularizes scientific progress on social media, and hosts events about bioethics and the future of humanity. Visit the platform at www.leaps.org. Podcast host Matt Fuchs is editor-in-chief of Leaps.org.

The government has weaponized healthcare with a program they call ARPA-H. Biden mentioned it in his State of the Union address. See what it means for the future ahead. DISCLAIMER: Views and opinions expressed on The Daniel Natal Show are solely those of the host and do not necessarily represent those of The New American. ... The post ARPA-H appeared first on The New American.

Dr. Renee Wegrzyn, Ph.D. is the inaugural director of the Advanced Research Projects Agency for Health ( ARPA-H - https://arpa-h.gov/ ), an agency that supports the development of high-impact research to drive biomedical and health breakthroughs to deliver transformative, sustainable, and equitable health solutions for everyone. ARPA-H's mission focuses on leveraging research advances for real world impact. Previously, Dr. Wegrzyn served as a vice president of business development at Ginkgo Bioworks and head of Innovation at Concentric by Ginkgo, where she focused on applying synthetic biology to outpace infectious diseases—including Covid-19—through biomanufacturing, vaccine innovation and biosurveillance of pathogens at scale. Prior to Ginkgo, Dr. Wegrzyn was program manager in the Biological Technologies Office at DARPA, where she leveraged the tools of synthetic biology and gene editing to enhance biosecurity, promote public health and support the domestic bioeconomy. Her DARPA portfolio included the Living Foundries: 1000 Molecules, Safe Genes, Preemptive Expression of Protective Alleles and Response Elements and the Detect it with Gene Editing Technologies programs. Dr. Wegrzyn received the Superior Public Service Medal for her work and contributions at DARPA. Prior to joining DARPA, she led technical teams in private industry in the areas of biosecurity, gene therapies, emerging infectious disease, neuromodulation, synthetic biology, as well as research and development teams commercializing multiplex immunoassays and peptide-based disease diagnostics. Dr. Wegrzyn holds doctorate and bachelor's degrees in applied biology from the Georgia Institute of Technology. She was a fellow in the Center for Health Security Emerging Leaders in Biosecurity Initiative and completed postdoctoral training as an Alexander von Humboldt fellow in Heidelberg, Germany. Support the show

In this special episode in front of a live audience at the Stanford School of Medicine, Dean Lloyd Minor welcomes Renee Wegrzyn, inaugural director of the Advanced Research Projects Agency for Health, known as ARPA-H, within the National Institutes of Health. They explore Renee's vision and roadmap for the new agency, which was established in 2022 with the mission of accelerating high-impact research to drive transformative solutions in health and health care.  Renee outlines the agency's model for rapidly developing groundbreaking innovations and how her experience at the Defense Advanced Research Projects Agency informs her leadership of ARPA-H. She also discusses the importance of public-private collaborations, leveraging sophisticated technological platforms, and engaging diverse perspectives in advancing breakthroughs to address the most pressing challenges for patients and communities.

The growth in skepticism about science that was fueled by disinformation during the pandemic has been a frequent topic on Raise the Line, with many insightful guests from medicine and academia offering analysis of the problem and possible solutions. On today's episode, we'll hear from someone who is very well-placed to actually make progress on this front. Max Bronstein, the Assistant Director for Health Innovation at the White House Office of Science and Technology Policy, joins host Shiv Gaglani to discuss the broad support President Biden has provided for science – elevating his science advisor to the cabinet level being a prime example – and also provide details about programmatic investments that tell the tale at a deeper level. At the top of Bronstein's list of examples is the launch of the Advanced Research Projects Agency for Health, also known as ARPA-H, which aims to drive transformative biomedical and health breakthroughs with a focus on equity. “The mission is about making sure there are cures for diseases, better diagnostic platforms and better technologies out there, but also making sure those are actually available to all Americans.” Don't miss this inside look at new efforts to strengthen the biotechnology workforce, broaden access to clinical genetic sequencing, advance development of treatments for rare diseases, and much more as a new era in health innovation gets underway.  Mentioned in this episode: https://www.whitehouse.gov/ostp/

Biden via his handlers: "Nice pipeline ya got there. It would be a shame if something happened to it!"As difficult as it might be to believe, the Biden regime - or those behind him, propping him like "Weekend at Bernies," have clearly stated as their goal to facilitate (via executive order and funding) to “write circuitry for cells and predictably program biology in the same way in which we write software and program computers.”As pointed out by Joe Allen in his substack article, '[o]ne day after signing his transhuman executive order, the obviously unenhanced Joe Biden announced that Renee Wegryzn will be the inaugural director of the new agency ARPA-H—the Advanced Research Projects Agency for Health. The agency is slated to receive $1 billion at present, although Biden is pushing for a stunning $6.5 billion."We are being fast-tracked to become largely tranhumanistic and subservient to the globalists (or dead). One big step is via the economy. In this episode, Doug Hagmann provides the details.IMPORTANT LINKS:DONATE: (www.HagmannReport.com/donate)HAGMANN COFFEE & MORE: (www.HagmannStore.com)The Hagmann Report provides news and information based on a combination of exclusive investigative work, proprietary sources, contacts, qualified guests, open-source material. The Hagmann Report will never be encumbered by political correctness or held hostage to an agenda of revisionist history.Join Doug Hagmann, host of the Hagmann Report, Weekdays @ 7 PM ET.ON THE GO? SUBSCRIBE TO HAGMANN'S PODCASTiTunes: (https://podcasts.apple.com/us/podcast/hagmann-report/id631558915?uo=4)Spotify: (https://open.spotify.com/show/376mkckQHCPYTJssQN794g)iHeart: (https://www.iheart.com/podcast/256-hagmann-report-30926499/)Spreaker: (https://www.spreaker.com/show/hagmann-report)Email: studio@hagmannreport.comFOLLOW HAGMANN AT:Parler: https://parler.com/DouglasHagmannGab: https://gab.com/DougHagmannGettr: https://gettr.com/user/doughagmannTruth Social: https://truthsocial.com/@DougHagmannTwitter: Twitter is garbage

Biden via his handlers: "Nice pipeline ya got there. It would be a shame if something happened to it!"As difficult as it might be to believe, the Biden regime - or those behind him, propping him like "Weekend at Bernies," have clearly stated as their goal to facilitate (via executive order and funding) to “write circuitry for cells and predictably program biology in the same way in which we write software and program computers.”As pointed out by Joe Allen in his substack article, '[o]ne day after signing his transhuman executive order, the obviously unenhanced Joe Biden announced that Renee Wegryzn will be the inaugural director of the new agency ARPA-H—the Advanced Research Projects Agency for Health. The agency is slated to receive $1 billion at present, although Biden is pushing for a stunning $6.5 billion."We are being fast-tracked to become largely tranhumanistic and subservient to the globalists (or dead). One big step is via the economy. In this episode, Doug Hagmann provides the details.IMPORTANT LINKS:DONATE: (www.HagmannReport.com/donate)HAGMANN COFFEE & MORE: (www.HagmannStore.com)The Hagmann Report provides news and information based on a combination of exclusive investigative work, proprietary sources, contacts, qualified guests, open-source material. The Hagmann Report will never be encumbered by political correctness or held hostage to an agenda of revisionist history.Join Doug Hagmann, host of the Hagmann Report, Weekdays @ 7 PM ET.ON THE GO? SUBSCRIBE TO HAGMANN'S PODCASTiTunes: (https://podcasts.apple.com/us/podcast/hagmann-report/id631558915?uo=4)Spotify: (https://open.spotify.com/show/376mkckQHCPYTJssQN794g)iHeart: (https://www.iheart.com/podcast/256-hagmann-report-30926499/)Spreaker: (https://www.spreaker.com/show/hagmann-report)Email: studio@hagmannreport.comFOLLOW HAGMANN AT:Parler: https://parler.com/DouglasHagmannGab: https://gab.com/DougHagmannGettr: https://gettr.com/user/doughagmannTruth Social: https://truthsocial.com/@DougHagmannTwitter: Twitter is garbage

As difficult as it might be to believe, the Biden regime - or those behind him, propping him like "Weekend at Bernies," have clearly stated as their goal to facilitate (via executive order and funding) to “write circuitry for cells and predictably program biology in the same way in which we write software and program computers.”As pointed out by Joe Allen in his substack article, '[o]ne day after signing his transhuman executive order, the obviously unenhanced Joe Biden announced that Renee Wegryzn will be the inaugural director of the new agency ARPA-H—the Advanced Research Projects Agency for Health. The agency is slated to receive $1 billion at present, although Biden is pushing for a stunning $6.5 billion."We are being fast-tracked to become largely tranhumanistic and subservient to the globalists (or dead). One big step is via the economy. In this episode, Doug Hagmann provides the details.IMPORTANT LINKS:DONATE: (www.HagmannReport.com/donate)HAGMANN COFFEE & MORE: (www.HagmannStore.com)The Hagmann Report provides news and information based on a combination of exclusive investigative work, proprietary sources, contacts, qualified guests, open-source material. The Hagmann Report will never be encumbered by political correctness or held hostage to an agenda of revisionist history.Join Doug Hagmann, host of the Hagmann Report, Weekdays @ 7 PM ET.ON THE GO? SUBSCRIBE TO HAGMANN'S PODCASTiTunes: (https://podcasts.apple.com/us/podcast/hagmann-report/id631558915?uo=4)Spotify: (https://open.spotify.com/show/376mkckQHCPYTJssQN794g)iHeart: (https://www.iheart.com/podcast/256-hagmann-report-30926499/)Spreaker: (https://www.spreaker.com/show/hagmann-report)Email: studio@hagmannreport.comFOLLOW HAGMANN AT:Parler: https://parler.com/DouglasHagmannGab: https://gab.com/DougHagmannGettr: https://gettr.com/user/doughagmannTruth Social: https://truthsocial.com/@DougHagmannTwitter: Twitter is garbage

As difficult as it might be to believe, the Biden regime - or those behind him, propping him like "Weekend at Bernies," have clearly stated as their goal to facilitate (via executive order and funding) to “write circuitry for cells and predictably program biology in the same way in which we write software and program computers.”As pointed out by Joe Allen in his substack article, '[o]ne day after signing his transhuman executive order, the obviously unenhanced Joe Biden announced that Renee Wegryzn will be the inaugural director of the new agency ARPA-H—the Advanced Research Projects Agency for Health. The agency is slated to receive $1 billion at present, although Biden is pushing for a stunning $6.5 billion."We are being fast-tracked to become largely tranhumanistic and subservient to the globalists (or dead). One big step is via the economy. In this episode, Doug Hagmann provides the details.IMPORTANT LINKS:DONATE: (www.HagmannReport.com/donate)HAGMANN COFFEE & MORE: (www.HagmannStore.com)The Hagmann Report provides news and information based on a combination of exclusive investigative work, proprietary sources, contacts, qualified guests, open-source material. The Hagmann Report will never be encumbered by political correctness or held hostage to an agenda of revisionist history.Join Doug Hagmann, host of the Hagmann Report, Weekdays @ 7 PM ET.ON THE GO? SUBSCRIBE TO HAGMANN'S PODCASTiTunes: (https://podcasts.apple.com/us/podcast/hagmann-report/id631558915?uo=4)Spotify: (https://open.spotify.com/show/376mkckQHCPYTJssQN794g)iHeart: (https://www.iheart.com/podcast/256-hagmann-report-30926499/)Spreaker: (https://www.spreaker.com/show/hagmann-report)Email: studio@hagmannreport.comFOLLOW HAGMANN AT:Parler: https://parler.com/DouglasHagmannGab: https://gab.com/DougHagmannGettr: https://gettr.com/user/doughagmannTruth Social: https://truthsocial.com/@DougHagmannTwitter: Twitter is garbage

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Biden should be applauded for appointing Renee Wegrzyn for ARPA-H, published by ChristianKl on September 18, 2022 on LessWrong. When Biden first announced ARPA-H (Advanced Research Projects Agency for Health) I was skeptical. At the time the proposal was to make ARPA-H a normal agency within the NIH. When critics argued that the NIH bureaucracy would likely reduce the amount of innovation that ARPA-H could produce the administration listened and US health secretary Xavier Becerra decided to make ARPA-H an independent entity within the NIH. Appointing Renee Wegrzyn as the head of ARPA-H is an excellent choice. Having previously worked at DARPA and IARPA and not in the NIH makes her a good person to copy the structure of how DARPA and IARPA get things done. Being 45, she is twenty years younger than the average director of an institute at the NIH who is 65. When science sometimes evolves from gravestone to gravestone, it's great to see a director for the ARPA-H who's in her forties. Especially, in contrast to the newly appointed NIH director Lawrence A. Tabak who is a 71-year-old (a fact that his NIH biography omits) having a 45-year-old lead ARPA-H is a welcome surprise. While at DARPA, Wegrzyn worked on biosecurity and even gave a talk about the importance of biosecurity to the Long Now Foundation. It's valuable to have people who care about biosecurity at the top of organizations that direct a lot of research dollars. A lot of the research focuses either on directly curing diseases or on basic research but the research that focuses on producing tools for better research is historically underfunded. Wegrzyn experience as vice president of business development at Gingko Bioworks which is a unicorn biotech company that historically doesn't focus on curing diseases directly but providing tools to help other companies, gives me hope that ARPA-H will be able to fund research into producing better tools to deal with biological problems. During COVID-19 they worked on producing COVID tests which was likely a lesson in the flaws of government bureaucracy holding back innovation. In an interview she described her own research as being guided by the question of ‘what do we know about protein folding that can help us develop a totally new type of diagnostic?' I'm happy to see that and think it will lead to better research paths than having someone who focuses more on creating FDA approved drugs in charge of allocating research funding. She coedited Alzheimer's Disease Targets for New Clinical Diagnostic and Therapeutic Strategies in 2012. It seems to me that one of the more important issues in Alzheimers research funding is the overinvestment in the amyloid cascade hypothesis. The book gets that issue right when it argues “Until recently, the amyloid cascade hypothesis had been the predominant working hypothesis for AD pathogenesis. However, this hypothesis has been supplanted by what some have called the oligomer cascade hypothesis, which posits that Aβ oligomers, rather than fibrils, are the proximate neurotoxic agents in AD” I think she showed excellent judgment by writing a book that argued for directing our Alzheimer research dollar to other paths than the amyloid cascade hypothesis (that part isn't written by her directly). In the essay that she wrote herself, she argues “Drug discovery and development for the treatment of Alzheimer's disease would greatly benefit from biomarkers that are predictive of clinical outcomes to inform the selection of effective drug candidates, monitor dose safety and efficacy on treated cohorts, and identify or confirm the mechanisms of drug action in hopes of developing treatments that go beyond symptomatic relief and are disease modifying. The ability to monitor disease progression longitudinally during patient treatment will also be key to...

Link to original articleWelcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Biden should be applauded for appointing Renee Wegrzyn for ARPA-H, published by ChristianKl on September 18, 2022 on LessWrong. When Biden first announced ARPA-H (Advanced Research Projects Agency for Health) I was skeptical. At the time the proposal was to make ARPA-H a normal agency within the NIH. When critics argued that the NIH bureaucracy would likely reduce the amount of innovation that ARPA-H could produce the administration listened and US health secretary Xavier Becerra decided to make ARPA-H an independent entity within the NIH. Appointing Renee Wegrzyn as the head of ARPA-H is an excellent choice. Having previously worked at DARPA and IARPA and not in the NIH makes her a good person to copy the structure of how DARPA and IARPA get things done. Being 45, she is twenty years younger than the average director of an institute at the NIH who is 65. When science sometimes evolves from gravestone to gravestone, it's great to see a director for the ARPA-H who's in her forties. Especially, in contrast to the newly appointed NIH director Lawrence A. Tabak who is a 71-year-old (a fact that his NIH biography omits) having a 45-year-old lead ARPA-H is a welcome surprise. While at DARPA, Wegrzyn worked on biosecurity and even gave a talk about the importance of biosecurity to the Long Now Foundation. It's valuable to have people who care about biosecurity at the top of organizations that direct a lot of research dollars. A lot of the research focuses either on directly curing diseases or on basic research but the research that focuses on producing tools for better research is historically underfunded. Wegrzyn experience as vice president of business development at Gingko Bioworks which is a unicorn biotech company that historically doesn't focus on curing diseases directly but providing tools to help other companies, gives me hope that ARPA-H will be able to fund research into producing better tools to deal with biological problems. During COVID-19 they worked on producing COVID tests which was likely a lesson in the flaws of government bureaucracy holding back innovation. In an interview she described her own research as being guided by the question of ‘what do we know about protein folding that can help us develop a totally new type of diagnostic?' I'm happy to see that and think it will lead to better research paths than having someone who focuses more on creating FDA approved drugs in charge of allocating research funding. She coedited Alzheimer's Disease Targets for New Clinical Diagnostic and Therapeutic Strategies in 2012. It seems to me that one of the more important issues in Alzheimers research funding is the overinvestment in the amyloid cascade hypothesis. The book gets that issue right when it argues “Until recently, the amyloid cascade hypothesis had been the predominant working hypothesis for AD pathogenesis. However, this hypothesis has been supplanted by what some have called the oligomer cascade hypothesis, which posits that Aβ oligomers, rather than fibrils, are the proximate neurotoxic agents in AD” I think she showed excellent judgment by writing a book that argued for directing our Alzheimer research dollar to other paths than the amyloid cascade hypothesis (that part isn't written by her directly). In the essay that she wrote herself, she argues “Drug discovery and development for the treatment of Alzheimer's disease would greatly benefit from biomarkers that are predictive of clinical outcomes to inform the selection of effective drug candidates, monitor dose safety and efficacy on treated cohorts, and identify or confirm the mechanisms of drug action in hopes of developing treatments that go beyond symptomatic relief and are disease modifying. The ability to monitor disease progression longitudinally during patient treatment will also be key to...

Episode 2159: The Great Reset: Live From TPUSA Phoenix; If The Regime Continues To Go Unchecked, We Will Continue To See Destruction; ARPA-H: From Healing/Enhancement, To Humanity 2.0

William Bonvillian does a deep dive about his decades of research on how DARPA works and his more recent work on advanced manufacturing.  William is a Lecturer at MIT and the Senior Director of Special Projects,at MIT's Office of Digital Learning. Before joining MIT he spent almost two decades as a senior policy advisor for the US senate. He's also published many papers and a detailed book exploring the DARPA model.  Links William's Website The DARPA Model for Transformative Technologies Transcript [00:00:35] In this podcast, William Bonvillian, and I do a deep dive about his decades of research about how DARPA works and his more recent work on advanced manufacturing. Well humans, a lecturer at MIT and a senior director of special projects at MIT is office of digital learning. Before joining MIT. He spent almost two decades as a senior policy advisor for the us Senate. He's published many papers and a detailed book exploring the DARPA model. I've wanted [00:01:35] to compare notes with him for years. And it was a pleasure. And an honor to finally catch up with him. Here's my conversation with William [00:01:42] Ben: The place that I I'd love to start off is how did you get interested in, in DARPA and the DARPA model in the first place you've been writing about it for more than a decade now. And, and you're probably one of the, the foremost people who who've explored it. So how'd you get there in the first. [00:01:58] William: You know, I, I I worked for the us Senate as a advisor in the Senate for for about 15 years before coming to MIT then. And I I worked for a us Senator who is on the on the armed services committee. And so I began doing a substantial amount of that staffing, given my interest in science technology, R and D and you know, got early contact with DARPA with some of DARPA's both program managers and the DARPA directors, and kind of got to know the agency that way spent some time with them over in their [00:02:35] offices. You know, really kind of got to know the program and began to realize what a, what a dynamic force it was. And, you know, we're talking 20, 20 plus years ago when frankly DARPA was a lot less known than it is now. So yeah, just like you know, kind of suddenly finding this, this Jewelbox varied in the. It was it was a real discovery for me and I became very, very interested in the, kind of the model they had, which was so different than the other federal R and D agencies. [00:03:05] Ben: Yeah. And, and actually um, It sort of in your mind, what is the for, for people who I, I think tend to see different federal agencies that give money to researchers as, as all being in the same bucket. What, what do you, what would you describe the difference between DARPA and the NSF as being [00:03:24] William: well? I mean, there's a big difference. So the NSF model is to support basic research. And they have, you know, the equivalent of project [00:03:35] managers there and they, they don't do the selecting of the research projects. Instead they queue up applicants for funds and then they supervise a peer review process. Of experts, you know, largely from academia who evaluate, you know, a host of proposals in a, in a given R and D area mm-hmm and and make valuations as to which ones would qualify. What are the kind of best most competitive applicants for NSFs basic research. So DARPA's got a different project going on, so it doesn't work from the bottom up. It, it has strong program managers who are in effect kind of empowered to go out and create new things. So they're not just, you know, responding to. Grant applications for basic research, they come into DARPA and develop a [00:04:35] vision of a new breakthrough technology area. They wanna stand up. And so it's, and there's no peer review here. It's really, you hire talented program managers. And you unleash them, you turn them loose, you empower them to go out and find the best work that's going on in the country. And that's, that can be from, from universities and often ends in this breakthrough technology area they've identified. But it also could be from comp companies, often smaller companies and typically they'll construct kind of a hybrid model where they've got academics. Companies working on a project, the companies are already always oriented to getting the technology out the door. Right. Cause they have to survive, but the researchers are often in touch with some of the more breakthrough capabilities behind the research. So bringing those two together is something that the program manager at DARPA does. So while at [00:05:35] NSF, the program manager equivalent, you know, their big job is getting grant out the door and supervising a complex selection process by committee mm-hmm . The role of the, of the ARPA of the, of the DARPA program manager is selecting the award winners is just the beginning of the job. Then in effect you move into their home, right? You work with them on an ongoing basis. DARPA program managers are spending at least one third of their time on the road, linking up with their, you know, with their grantees, the folks they've contracted with sort of helping them along in the process. And then, you know, the typically fund a group of research awards in an area they'll also work on putting together kind of a thinking community amongst those award winners. Contract winners so that they begin to share their best ideas. And that's not a, that's not easy, right? Yeah. Yeah. If you're an academic [00:06:35] or you, a company, you stuff, you trading ideas is a complicated process, but that's one of the tasks. That the DARPA program manager has, is to really build these thinking communities around problems. And that's what they that's what they're driven to do. So it's a very, very different situation. This is, this is the different world here that Dar is created [00:07:01] Ben: and, and sort of actually to, to, to click on The, the how DARPA program managers interact with ideas. Do you have a sense of how they incentivize that idea sharing? Is it just the, the concept that if you share these ideas, they might get funded in a way that they wouldn't or like what, how do they sort of construct that That trust that people for people could actually be sharing those ideas. [00:07:28] William: Yeah. In, in some ways then it starts out at an all stage. So before, you know, a new [00:07:35] program manager arrives at DARPA and often they'll have, I mean, this could be ape. It could be I RPA, which worked slightly different ways, but similar kind of approach RPE is our energy DARPA. I, APA is our intelligence Dar. Right. And then soon we'll have a help DARPA, which has now been funded. Yeah. I wanna [00:07:55] Ben: your opinion on that later. [00:07:57] William: Okay. Well, we're working away on this model here. You know, you hire a program manager and you hire somebody. Who's gonna be, you know, talent and dynamic and kind of entrepreneurial and standing up a new program. They get the DARPA and they begin to work on this new technology area. And a requirement of DARPA is that really be a breakthrough. They don't wanna fund incremental work that somebody else may be doing. They wanna find a new, new territory. That's their job, revolutionary breakthroughs. To get there. They'll often convene workshops, 1, 2, 3 workshops with some of the best thinkers around the country, including people, [00:08:35] people who may be applying for the funding, but they'll, they'll look for the best people bringing together and get, you know, a day long process going um, often in several different locations to kind of think through. Technology advance opportunity. How, how it might shape up what might contribute, how might you organize it? What research might go into it, what research areas and that kind of begins the kind of thinking process of building a community around a problem. And then they'll make grant awards. And then similarly, they're gonna be frequently convening this group and everybody can sit on their hands and keep their mouth shut. But you know, that's not often the way technologists work. They'll get into a problem and start wanting to share ideas and brainstorm. And that's, that's typically what then takes place and part of the job of the, of. Partner manager DARPA is to really encourage that kind of dialogue and get a lot of ideas on the table and really promote it. Yeah. [00:09:34] Ben: [00:09:35] And, and then also with, with those ideas do, do you have, like, in your, your having looked at this so much, do you have a sense of how much there there's this tension? You know, it's like people generally do the best research when they feel a lot of ownership over their own ideas and they feel like they're, they're really working on. The, the thing that they want to work on. But then at the same time to sort of for, for, for the, a project to play into a broader program, you often need to sort of adjust ideas towards sort of a, a bigger system or a bigger goal. Do you have, do you have an idea of how much Program managers sort of shape what people are working on versus just sort of enabling people to work on things that they would want to work on. Otherwise. [00:10:24] William: Yeah. The program manager in communication with DARPA's office directors and director. Right, right. So it's a very flat organization. You know, and [00:10:35] there'll be an office director and a number of program managers working with that office director. For example in the field of, of biological technologies, a fairly new DARPA office set up about a decade ago. Yeah. You know, there'll be a group of DARPA program managers with expertise in that field and they will often have often a combination of experiences. They'll have some company experience as well as some academic research experience that they're kind of walking on both sides. They'll come into DARPA often with some ideas about things they want to pursue, right. And then they'll start the whittle down process to get after what they really wanna do. And that's, that's a very, very critical stage. They'll do it often in dialogue with fellow program managers at DARPA who will contribute ideas and often with their office. Who kind of oversees the portfolio and we can feed that DARPA program manager into other areas of expertise around DARPA. So coming up with a big breakthrough idea, then [00:11:35] you test it out in these workshops, as I mentioned, right. As well as in dialogue with your colleagues at DARPA. And then if it looks like it's gonna work, then you can move it rapidly to the approval process. But DARPA is, you know, I mean, it's what its name says. It's advanced research projects agency. So it's not just doing research. It very much wants to do projects. And you know, it's an agency and it's a defense agency, so they're gonna be, have to be related to the defense sector. Although there's often spill over into huge areas of civilian economy, like in the it world really pioneer a lot. But essentially the big idea to pursue that's being developed by the program manager and refined by the program manager. And then they'll put out, you know, often what's called a broad area announcement, a BIA. We wanna get a technology that will do this. Right. Right. Give us your best [00:12:35] ideas. And put this out, this broad area announcement out and get people to start applying. And if it's, if the area is somewhat iffy, they can, you know, proceed with smaller awards to see how it kind of tests out rather than going into a full, larger, larger award process with kind of seedlings they'll plant. So there's a variety of mechanisms that it uses, but getting that big breakthrough revolution or idea is the key job at a program manager. And then they'll, they're empowered to go out and do it. And look, Dora's very cooperative. The program managers really work with each other. Yeah. But in addition, it's competitive and everybody knows whose technology is getting ahead, whose technology is moving out and what breakthroughs it might lead to. So there's a certain amount of competition amongst the program managers too, as to how their revolution is coming along. Nice. [00:13:28] Ben: And, and then sort of to, to go sort of like one level down the hierarchy, if you will. When [00:13:35] they put out these, these BAAs do you have a sense for, of how often the performers will sort of either shift their focus to, to, towards a APA program or like how much sort of haggling is there between the performer and the, the program manager in terms of Sort of finding this balance between work that supports the, the broader program goals and work that sort of supports a researcher's already existing agenda. Right. Because, you know, it's like people in their labs, they, they sort of have this, the things that they're pursuing and maybe they're, they're like sort of roughly in the same direction as a program, but need to be, need to be shifted. [00:14:20] William: Yeah. It's, you know, the role of the program manager is to put out a new technological vision, you know, some kind of new breakthrough territory. That's gonna really be a very significant [00:14:35] advance that can be implemented. It's gonna be applied. It's not discovery. It's implementation that they're oriented to. They want to create a new thing that can be implemented. So they're gonna put the vision out there and look the evaluation process. Is gonna look hard at whether or not this exact question you're raising. It's gonna look hard at whether or not the, the applicant researcher is kind of doing their own thing or can actually contribute to the, to the implementation of the vision. And that's gonna be the cutoff. Will it serve the vision or not? And if it's not, it's not gonna get the award. So look, that's an issue with DARPA. DARPA is going at their particular technology visions. NSF will fund, you know, it's driven by the applicants. They will think of ideas they wanna pursue and see if they can get NSF funding for it at DARPA's the other way around the program manager has vision [00:15:35] and then sees who's willing to pursue that vision with him or her. Yeah. Right. So it's a, it's more of a, I won't say top down because DARPA's very collaborative, but it's more of a top down approach than as opposed to NSF, which is bottom up. They're going for technology visions, not to see what neat stuff is out there. right. [00:15:56] Ben: Yeah. And just to, to shift a little bit you, you mentioned I a RPA and ARPA, E as, as other government agencies that, that used the same model you wrote an article in 2011 about ARPA E and, and I I'm interested in. What like how you think that it has played out over, over the past decade? Like how, like how well do you think that they, they have implemented the model? Do you think that it, it does work there. And like what other places do you think, I guess do, do you have a sense of like how to know whether a DARPA, the DARPA [00:16:35] model is applicable to an area more broadly? [00:16:39] William: Yeah. I mean, look that's, and that's kind of a, that's kind of a key question, you know, if you wanna do a, if you wanna do a DARPA, like thing, is it gonna work in the territory that you wanna work in? But let's, let's look at this energy issue. You know, I was involved in, you know, some of the early discussions about creating an, a. For for energy and, you know, the net result of that was that Congressman named bar Gordon led an effort on the house science committee to really create an ARPA energy. And, and that approach had been recommended by a national academies committee. And it you know, it seemed to make a term on a sense. So what was going on in energy at the time of formulation of this. Like the 2007 rough time period. You know, 2008, what was happening was that there was significant amount of investment that was moving from, in, [00:17:35] in moving in venture capital towards new energy, clean tech technologies. So the venture capital sector in that timetable was ramping. It's 2006, 2007 time period was ramping up its venture funding and Cleantech. And that's when AR was being proposed and consider. So it looks like it looked to us, looks everybody, like there would be a way of doing the scale up. Right. In other words, it's not enough just to have, you know, Cool things that come out of an agency, you need to implement the technology. So who's gonna implement it. Right. Who's gonna do that scale up into actual implementation. And that's a very key underlying issue to consider when you're trying to set up a DARPA model. DARPA has the advantage of a huge defense procurement budget. So, right. It can, you know, it can formulate a new technology breakthrough, like [00:18:35] saying stealth, right. Mm-hmm or in you know, UAVs and drones. And then it can turn to the defense department that will spend procuring money to actually stand up the model on a good day. Cause that doesn't always happen. doesn't always go. Right. But, but it's there, what's the scale up model gonna be for energy? Well, we thought there was gonna be venture capital money to scale up Cleantech. And then the bottom fell out of the Cleantech venture funding side in the 2008, 2009 time table and venture money really pulled out. So, you know, in 2009 is. Harpa E first received it, significant early funding. Got an appropriation of 400 million had been authorized for the science committee and then it got an appropriation. Could you say that again? And the there was a big risk there. So look, RPE was then created, had a very dynamic leader named Maju. Who's now at Stanford leading the energy initiatives there. Aroon [00:19:35] saw the challenge and he frankly rose to it. So if they weren't gonna get this, these technologies scaled up through venture capital, like everybody assumed would work. How are they gonna do scale up? So who did a whole series of very creative things? There was some venture left. So we maintained, you know, good relations with the venture world. But also with the corporate world, because there were a lot of corporations that were interested in kind of moving in some of these directions. If these new technologies complimented technologies, they were already pursuing, right. So room created this annual. RPE summit where all of its award winners would, you know, present their technologies and, you know, fabulous, you know, presentations and booths all around this conference. It rapidly became the leading energy technology conference in the us wide widely attended by thousands of people. Venture capital may not be funding much, but they were there. But more importantly, [00:20:35] companies were there. And, you know, looking at what these technologies were to see how they could get to get stood up. So that was a way of exposing what was RPE was doing in a really big way. Right. Right. Another approach they tried was very successfully was to create what they call the tech to market group. So in addition to your program manager at RPE, You stand up a new project and assigned to that project would be somebody with expertise in the commercialization of technology by whatever route the financing might be obtained. And they brought in a series of experts who had done this, who knew venture, who knew startups, who also knew federal government contracting in case the feds were gonna buy this stuff, particularly a D O D and this tech to market group became, you know, that was part of the discipline of standing up a project was to really make sure there was gonna be a pathway to commercialization. In fact, that approach. [00:21:35] Was so successful and DARPA for a number of years later hired away RPE tech tech to tech, to market director to run and set up its own tech to market program. Right. Which was, you know, the, the new child is just taught the parent a lesson here is what the, what the point was. So there's now a tech to market group at, at DARPA as well. Another approach they did. Was, you know, there's a, there's a substantial amount of other R and D funding, more incrementally oriented at the department of energy. The E E R E program, but other programs in different energy technology areas will support, you know, companies, company research, as well as academic research. So RP built very good ties. With E E R E the applied research wing for renewable energy and other applied research, arms of department of energy so that they could provide the kind of next stage in funding. So you do the [00:22:35] prototyping through APA E and then some of the scale up could occur through through. Some of the applied agencies within the department of department of energy. So that was, there were other things they attempted as well. But those were some of the most creative and, you know, they got around this problem. Now there's an underlying issue in energy technology and, and it's true for many. DARPA like approaches the technologies don't stand up overnight. In other words, you don't do your applied work and end up with an early prototype and expect it to become a major business within two weeks. Right. Right. That process can take 10 years or 15 years, particularly in the hard tech area. Right. Anything that requires manufacturing? Yeah. Energy technology stand up. That's a, that's a 10 to 15 year process in the United States. So RPS only been around what, you know, 11, 12 years, something like that. They're still, you know, their technology are still emerging. They have made a lot of [00:23:35] technology contributions in a lot of technology areas that have helped expand opportunity spaces. Yeah. In many interesting areas. So they really helped, I believe. In identifying kind of new territories where there can be advances. But you know, have we transformed the world and solve climate change because of RPE yet? No, no, that's, that's a longer term project. So you have to have that expectation when you look at these different story of software and in some it sectors, DARPAs played a huge role in the evolution of those. Those could be shorter. Yeah, but anything really in the heart tech area is gonna take a much more extended period. Yeah. So you have to be patient. The politicians can't expect change in two weeks or two years. They're gonna have to be a little more patient. [00:24:24] Ben: And, and another sort of just issue that I, I, I'm not sure is, is a real thing, but that I've noticed is that a difference between DARPA and RPE is that [00:24:35] with, with DARPA, when you have the, the DOD acquiring technologies, they can sort of gather together all the different projects that were in, in, within a program and sort of integrate them into an entire system where. When you have a, an ape E program ending there's, there are a number of different projects, but there, there, isn't a great way of sort of integrating all the different pieces of a program. Is that an accurate assessment or am I, am I off base on that? [00:25:07] William: No, Ben, I think that's, I think that's accurate. I know. I mean the part of energy doesn't have a procurement budget. Right, right. Like the defense department does, it's not spending 700 billion a year to make things. So it can't play that system scale up kind of role in the kind of way the defense department does. Now. Look, I, I don't wanna overstate this because DARPA has definitely stood up technologies outside of defense, above procurement. So [00:25:35] most of its it revolution stuff. Where it played a, you know, big role, for example, as you know, in the development of desktop computing and, and a huge role in, in supporting the internet development of the internet. Absolutely. You know, those got stood up, not particularly through DOD, they got stood up in the civilian sector. So DARPA, you know, works on both sides of the street here. If it appears advantageous to, to stand it up on the civilian side, let it scale up and then the can buy it. Right. Mm-hmm , it'll do that. But on the other hand, there's, you know, there's very critical areas. Defense's gonna have to be a lead on like, you know, GPS, for example and really scale up the system. And then it can be shifted over to serve a dual use. [00:26:22] Ben: And, and then, so, so sort of like looking forward to the, the future how do you see all these considerations playing out with with ARPA H the, the health ARPA that is, I think been approved, [00:26:35] but hasn't actually started doing anything yet. [00:26:39] William: Yeah. It's got money appropriated. So you, and it's a priority of the. Of the current administration. So, you know, I believe it's gonna happen here. I mean, look, you know, there, there's some things that just need to be in place for a DARPA model to work well, mm-hmm, scale up is one that we've talked about and, you know, there is a pathway to scale up for new breakthroughs in in, you know, biomedicine and and, and medical device. We've got strong venture capital support in that area for a series of historical reasons. So that follow one pickup in many fields, right, is gonna be is gonna be available in many biomedical kind of fields. Know, there are issues. There, there was a big debate about an issue that I'll call island bridge, right? What you want, what you wanna do [00:27:35] with your DARPA is you want to put your, your DARPA team on an island. You wanna protect that island and keep the bureaucracy away from it. Right? Let 'em do their thing out there and do great stuff. And don't let the bureaucracy, the suits interfere with them. Yeah. On the other hand, they really need a bridge back to the mainland to get their technologies scaled up. So DARPA, for example, reports to the, in effect to the secretary defense and can undertake projects that the secretary defense can then, you know, in effect force the military services to pick up or, you know, use, use budgeting authority to encourage the military services to pick up DARPA has it's an island. It's got a separate building. It's about five miles away from the Pentagon. It's got its team there. It's got its own established culture. But then it's got a bridge back to the mainland, through the secretary of defense, into the defense procurement system. What's gonna be ARPA HS [00:28:35] relationship there. So there've been a lot of. About where to put ARPA-h do you put it in NIH, which is another, like NSF, another peer review, basic research agencies by far the biggest it's got its own culture and that culture frankly, is not a DARPA culture, right? That's not a strong program manager culture. It's a peer review culture. Do you really want to put your DARPA like thing within NIH? And within that NIH culture on the other hand, where else are you gonna put it? Right. So at the moment we've gotta compromise the ARPA H is gonna report to the secretary of HHS, but the secretary of HHS. Doesn't have money to scale up new technologies to speak up. Right. Right. There is an assistant secretary of health who oversees BARDA and some other entities. So, you know, that's, that's a possibility. But NIH has got a lot of ongoing research going on. [00:29:35] There could be a lot of following research that came out of NIH, NIH. So it's, this is a challenge. This is a challenge to set up the right kind of island bridge model for this new ARPA H. We've kind of got a compromise there at the moment. It will be located somewhere on the NIH campus. Hopefully in a separate, you know, building or location. Yeah. And then report to the secondary of HHS. But how are these, how is this scale up gonna work here? What's the bridge to the mainland gonna be and will it be protected enough from a very different culture at NIH? With lots of look, lots of jealousies, you know, when RPE was created for energy, the labs saw the, you know, there's 14 major energy labs, right? They saw RPE as a big competitor for funding that was gonna take money away from the labs. It took a long time to build those relationships so that the lab saw RPE, not as a competitor, but as a way in which their stuff could help. Move ahead. [00:30:35] Yeah. Uh, And that took a while to kind of sort out. So there's a series of these issues that are gonna have to get well thought through for for this new ARPA H that opening culture is absolutely critical. Say more about that and it, yeah. In other words, the culture of strong program managers that are empowered and ready to pursue breakthrough technologies. That's the heart of the darker culture, that culture locks in, in the opening months. If you get it wrong, it's very hard to fix it later. You really can't go back. Yeah. So hiring the right people, having a DARPA director who understands, for example, an ARPA age director who really understands the DARPA model and how to implement it that's gonna be key in setting that culture upright to the. [00:31:23] Ben: Yeah. And, and, and you've mentioned a, a couple of times the, sort of the effect of physical location on, on the culture. Have you, have you seen that, that, like where [00:31:35] people are physically located really like have an effect on, on resulting cultures? [00:31:41] William: Yeah. I mean, look, obviously post pandemic, we're exploring remote work a lot. Yes. But there's a lot to be said for getting your, your thinking team in one place where they're bouncing off ideas, each other with each other all the time. Yeah. Where they're exposed and, and critiqued and evaluated. And they just can't see each other, remind each other kind of all the time. So creating that island. With your talent on it so that they can interact and, and inevitably work pretty intensively together. Yeah. That's a, you know, I think that's a, something of a prerequisite to getting these kinds of organizations together. You've gotta build that earliest free to core and that early culture that that's very empowered. [00:32:30] Ben: And, and so just sort of to, to take, to take a, a right turn [00:32:35] and, and talk a little bit about your, your work on, on advanced manufacturing. This is, this is an area I personally know much less about. But like, I guess one, one sort of basic thing is I think a lot of people Like don't have a good sense of what sort of advanced manufacturing actually means. Like what, what is, what is, what, what, what does advanced actually entail in this situation? [00:33:00] William: Yeah, let me, let me tell you know, a little bit of a story here. Yeah, please. The there are a suite of new technologies. Corresponding processes that are kind of emerging, right. And some have, you know, some have emerged. Some are earlier at an earlier stage but areas like robotics, you know, 3d printing, additive manufacturing obviously digital digital production technologies. Where it is built into kind of every stage. All of your factory floor equipment is all [00:33:35] linked. You're doing continuous analytics on each machine, but then able to connect them to see the processes as a whole that kind of it revolution side. Then there's a whole series of advances in critical, you know, materials. that will enable us to do kind of designer materials in a way we've never done before, because we can now really operate at the medical level in designing materials. So, you know, we can have, you know, in the, in the clean tech space or automotive space, for example, we can have much lighter, much stronger materials. And in a related area, composites are now, you know, an emerging opportunity space. For a lot of, kind of new manufacturing. We may be able to do electronics, which is a whole new generation of electronics based on light and with whole kind of range of new speed for electronics as a result of that and new efficiencies. So there's a lot of technologies that are, that are [00:34:35] available. Some are starting to enter. Some are further back like Flo for example. But they could completely transform the way in which we make things. And that's what advanced manufacturing is. Can we move to these new technologies and, and the processes that go with them in completely transforming the way in which we make. [00:34:57] Ben: Yeah. And, and like, so, so this is, I'm very interested in this and it, it feels like there isn't like, like sort of answering that question involves real research. Right? Cause you, you sort of need to, to rethink processes, you need to rethink how you do design. But at the same time, there, there aren't a lot of. Institutions that are, are organized to do that sort of research. [00:35:23] William: Yeah, that's look that this has been a big gap in our R and D portfolio in the United States. So at the end of world war II, Ben you know, veever Bush designs, the postwar [00:35:35] system for science. Right, right. So. We do this amazing connected system in world war II. We have industries working with universities, working with government that're closely tied. We do incredible advances that lead to, you know, the, they lead to the electronics industry. They lead to the whole aerospace industry, right at the kind of scale we have now, they lead to, they lead to nuclear power. Amazing stuff comes out of world war. I. And we had a very connected system. Then we, we dismantled the military at the end of the work. Cause we thought mistakenly there was gonna be world peace and all those 16 million, you know, soldiers, sailors, airmen that are overseas start to come home and VIN Bush steps in and he says, wait a minute, let's hang on to some of this. We built this amazing R D capability in the course of the war. Let's hold on to some of it. So he says let's support basic research. That's the cheapest stage, right? Applied research costs a lot more. Yep. So we decided let's hang onto that. [00:36:35] And then we began during the war with a lot of federal research funding and universities really for the first time. So my school MIT got 80 times. Amount of federal research funding in four years of world war II, as it did in all of its previous 80 years of history, wow. That's happening at a whole bunch of schools. We're creating this incredible jewel in the American system. We're creating the federally funded research university. So it leads to that which is big, positive, but neighbor Bush's basic research model leaves out the applied side. And the assumption he's got, it's kind of a, what he, what others refer to as a pipeline model. But the federal government role is let's dump basic research into one end of the innovation pipeline. Let's hope that mysterious things occur and great products emerge. Right. And it's the job of industry to do that interim stage. That's kind the model. That is what it, [00:37:35] your fingers hoping something is gonna happen in that pipeline. And whereas in world war II, every stage that pipeline was pretty well organized in a coordinated kind of way. So we move away from that world war II connected system to a very disconnected system. We in effect institutionalized the valley of death, right. There's gonna be a gap between research side and on one side of the valley. And. You know, the actual technology implementation applied late stage applied side on the other side of the valley with a big gap, big valley gap in between the two and very few bridging mechanisms across. So we built that into our system. And look, VIN Bush was worried about science. How are we gonna fund basic science? That's his worry. And we built, you know, the us, wasn't the science leader going into world war II. Yeah. Germany, Britain, war. We weren't, we managed [00:38:35] to bring over lots of immigrants to help lead science in the us. And they, they took up the reigns and we trained a lot of great talent here in the course of the war. And you know, we got ourselves in a position where the us was the science leader by the end of the. We were going into the war, the world manufacturing leader. We weren't the science leader. We were the world manufacturing leader. We had built a system of mass production that nobody else had ever seen. Right? Yeah. We went into the war with eight times the production capacity of Japan and four times the production capacity in Germany going into the war. You can only imagine what were coming outta the war. Yeah, exactly. So the least thing on Genever Bush's mind was manufacturing that's in great shape. He sort [00:39:24] Ben: took that as a given [00:39:25] William: almost right. That's a given we're always gonna have that. Right. But he was wrong. We weren't always gonna have that. Uh, And Japan taught us, [00:39:35] you That ended up costing the us it's electronic sector leadership in the electronic sector and leadership in the auto sector, two industry sectors that we had completely dominated. So, and then, you know, comes to China and we have further erosion as well. So the reason why advanced manufacturing is important is you. We, we got two moves to compete with China. China's lower wage, lower cost. We can lower our wages to Chinese wage levels. That's probably not gonna happen. Right. Or alternatively, although we've been working on it, cause we've definitely stagnated wages in us, manufacturing, believe me. But secondly, we can get much more efficient, much more productive. We can apply our innovation system to manufacturing. Right. So NSF doesn't have an R and D portfolio related to manufac. Star doesn't have an R D portfolio that's terribly related to manufacturing either. Right? NIH certainly [00:40:35] doesn't we don't do manufacturing. We don't do these manufacturing technologies and processes in our I D system. Let's get that very talented, still very able us innovation system onto manufacturing. So that's the basic idea and that's the way we're gonna have to compete. We sort of got no other move. Right? We can just have continued erosion with all kinds of social disruption. And a real decline in the American working glass, we can continue to do that and we watch what that's doing to our democracy, or we can get our act together and do advanced manufacturing. Yeah. And, and [00:41:12] Ben: do you look, I guess, like, what are some of the most sort of promising efforts in that area, in, in that you've seen? [00:41:21] William: Well, there's, there's amazing work going on that we already see in a whole new kind of robotics. You know, the old industrial robots weighed 10 times. They're very dangerous. You have to put cages around them and make sure that the workers don't go near them. [00:41:35] And they do, you know, they lift up something heavy and they'll do like one perfect spot weld, and then they'll move to the next, you know, next piece of, you know, next piece, moving down the assembly line. Yeah. That's the old kinda robotics. The new kind of robotics are lightweight, collaborative robotics. Just as you know, we're talking on cell phones, it's like the relationship between me and the cell phone. It's a big enabler for me. It helps me I can do voice commands to the robot and it's, you know, and can work in a precision kind of way, but it was also knows me works around me. Doesn't endanger. It's a helper, not a, you know, a caged beast that has to be behind a fence. So we're moving to that kind of new robotics. That's a whole new C change in manufacturing. We're doing 3d printing, which you know, is instead of. Instead of subtractive manufacturing, where you cut away a huge piece of metal [00:42:35] and end up with a smaller part with real limits to what the shape and dimensions and content of that, that, that part can be additive enables you to build a part from scratch with these, with powders shape it to exactly the role you want often with new materials and we're moving into. Metal 3d printing. So it's no longer plastics and resins only, it's a whole new kind of it's metal of production. And look, you know, we haven't figured out yet how to get the volumes that are similar to, to mass production for 3d printing, but there are plenty of product lines where you you're making limited numbers that are, have to be extremely precise, right? Yeah. Like. Jet engines, right. You know, you're not turning out millions of jet engines every day. You're turning out small numbers, but the precision that additive [00:43:35] can bring potentially with new materials, like ceramics to creating those turbine blades is really quite dramatic. So there's a whole series of industrial sectors that'll be suited to, to additive. And that's already moving in on some of these sectors and we're learning how to. All kinds of, of new materials for additives, you know, particularly in the metal side and new material side. So that's another huge territory of opportunity to transform their actually new ways. [00:44:03] Ben: And, and something that I'm particularly interested in is, is so. You could think of, of many of these, these new technologies as sort of components in a broader system. And what it seems like I, I don't personally see a lot of, is kind of like the like process research work to really sort of rethink the entire The the, the entire, like, call it a manufacturing line or the entire system and sort of ask, like what, how would you like redesign the product around how you're making it? Have you seen any [00:44:35] sort of like institutions that are sort of trying to do that sort of work? [00:44:40] William: Yeah. I mean this, this whole idea of, you know, for a long time, you know, we gear. The design had to fit the manufacturing, right? So we moved to, you know, design for manufacturing, right. To make it easily manufacturable. But now. The manufacturing can be much more embedded into the design process because you can come up with a whole new suite of capabilities that will effectuate new design opportunities. Right? So rather than manufacturing, being a limiting factor on, on design, it's a, it's now an enabler of design and additive manufacturing is an example of. So a whole new relationship between the production process and design process really possible here with these new technologies. And then getting back to your systems point. You know, now we've got the opportunity through digital [00:45:35] technologies to really take a look at a production. Operation, not as this, a series of isolated machines where material has to be carted from one machine suite to the next machine suite. Right now we've got the ability to integrate them in, in ways that we have never had before with running the kind of level of data analytics on, on performance for each machine, but also running a new level of analytics on the system itself. Right? So we're now in a position to really connect, collect the metrics. To a very fine scale and level on the production process itself in a way that we've never really had before. So the opportunities for efficiencies here I think are quite dramatic. And I think that's the way we're gonna have to compete. But a lot of people worry, you know, are we gonna eliminate all work? Right? Are the, are the robots gonna displace the workers? But the reality of advanced manufacturing is actually something [00:46:35] of the opposite. You know, the robot will display some jobs, but much more frequently, the robot will create all kinds of new possibilities within existing jobs. Yeah. And then thirdly, there will be jobs to get created because we need to make robots right. And operate program. And so they're gonna be a lot of jobs. So the net job loss problem, I just don't think is a real. Right. Yeah. Instead we get these new possibilities of kind of moving ahead and look at the center of these kinds of new factory systems are gonna be people, right? Yeah. People in the are the ones that have ideas you know, software and AI. And robotics just can't do a whole lot of things that people are, are able to do. They don't have the kind of conceptual frameworks and the ability to kind of Intuit [00:47:35] change that people have got. So I think in a way the new manufacturing system is going be, you know, more people centric than it's been before. Instead [00:47:47] Ben: of people just acting like robots. [00:47:49] William: Yeah. Lot people act acting like robots. It's people, you know, doing the organization and designing and management and the systems and the programming and the processed way that we're gonna need. Yeah, [00:48:07] Ben: This was awesome. I'm so grateful. And now a quick word from our sponsors. If you listen to podcasts you've surely heard about advertisements for all sorts of amazing mattresses ones that can get hot or cold firmer or softer but now with the pod you can sleep in a tank of hydrostatic fluid make gravity while you sleep a thing of the past [00:48:35]  

On the latest BioCentury This Week podcast, Washington Editor Steve Usdin details how the Advanced Research Projects Agency for Health is taking shape as the new U.S. agency seeks to deliver transformative science and the latest moves by Rep. Anna Eshoo to change its structure via legislation. The podcast team also explores the U.K. NHS's deal with Pfizer Inc. and Shionogi & Co. Ltd. on a subscription-based payment pilot for antibiotics, which could serve as an example for other payers considering similar initiatives; why an IP agreement by the WTO will do little to move the needle on COVID countermeasures; and top takeaways from Zai Lab CEO Samantha Du on The BioCentury Show. In addition, they call for members of the biopharma community to participate in a BioCentury survey on the talent crunch facing industry. All responses will remain confidential.

A new DARPA styled agency called Advanced Research Projects Agency for Health (ARPA-H) has been newly created and is the agency behind Biden's stated goal to cure cancer. It is doubtful whether the agency has the fortitude to “cure” cancer at the expense of big pharma, but it will likely do much more than we will ever know. Considering most DARPA projects are black, it is likely ARPA-H projects will be black too. But, this report shares some of what we do know to this point.

A new DARPA styled agency called Advanced Research Projects Agency for Health (ARPA-H) has been newly created and is the agency behind Biden's stated goal to cure cancer. It is doubtful whether the agency has the fortitude to “cure” cancer at the expense of big pharma, but it will likely do much more than we will ever know. Considering most DARPA projects are black, it is likely ARPA-H projects will be black too. But, this report shares some of what we do know to this point. See sources used in this report: ARPA-H, New DARPA Styled Agency created to restructure the National Institute of Health (NIH)   Please help us fight for Freedom of Speech, consider donating @ givesendgo.com/DefendingFreeSpeech Important Proven Solutions to Keep from Getting Sick Even if you Received the mRNA Shot Protect your family and your assets with Silver & Gold - Contact info@milesfranklin.com, tell them "Sarah sent you" and receive excellent service and the lowest prices in the country, guaranteed! MUSIC CREDITS: Intro music by Media Music Group and "Do You Trust Me" by Michael Vignola, licensed for broad internet media use, including video and audio       See video on Bastyon | Bitchute | Rumble | Odysee | Freedom.Social | SarahWestall.tv      

On the heels of SOFIC, our researchers brief us on some major developments in the federal IT space. Most notably, there is the formation of the Biden-backed ARPA-H at NIH to improve government's ability to speed biomedical and health research, and also the rollout of the Defense Department's new Chief Digital and AI Office. Senior Researcher Melissa Harris and Staff Writer Nikki Henderson break down what these updates mean.

DOE's Frontier supercomputer is named fastest in the world; HHS launches ARPA-H; CISA, DHS, and DoD propose 5G Security Evaluation Process, and more. For more news and insights on today's mission-critical IT challenges, check us out on MeriTV.

DOE's Frontier supercomputer is named fastest in the world; HHS launches ARPA-H; CISA, DHS, and DoD propose 5G Security Evaluation Process, and more. For more news and insights on today's mission-critical IT challenges, check us out on MeriTV.

Today's guest is Percy Griffin, director of scientific engagement for the Alzheimer's Association, a nonprofit that's focused on speeding up research, detecting Alzheimer's earlier and other risk reduction measures. Percy has a doctorate in molecular cell biology from Washington University. He's led important research on Alzheimer's, and he's a gifted science communicator. His bio is linked in the show notes, below.The topic of our conversation is the present and future of the fight against dementia. Billions of dollars have been spent by the National Institutes of Health and biotechs to research new treatments for Alzheimer's and other forms of dementia, but so far there's little to show for it. Last year, Aduhelm became the first drug to be approved by the FDA for Alzheimer's in 20 years, but there have been red flags about its effectiveness, side effects and cost.Meanwhile, 6.5 million Americans have Alzheimer's.Show notes:4:40 - What led Percy to concentrate on working in this important area.6:20 - Defining Alzheimer's, dementia, and the key elements of communicating science.10:20 - Why the Alzheimer's Association has supported Aduhelm.17:58 - Reason to be excited about therapeutics under development and how they could be tailored to a person's unique biology.24:25 - Tradeoffs between investing more money into Alzheimer's research compared to other intractable diseases like cancer, and new opportunities to accelerate progress, such as President Biden's ARPA-H proposal.27:24 - The social determinants of health. The pros/cons of continuing to spend billions to develop new drugs versus expanding policies for better education, nutritious food and safe drinking water that have enabled some groups more than others to enjoy improved cognition late in life.34:18 - Percy's top lifestyle recommendations for protecting your mind.37:33 - Is napping bad for the brain?39:39 - Circadian rhythm and Alzheimer's.42:34 - Tests to check brain health today, and which biomarkers we're making progress on.47:25 - Important programs run by the Alzheimer's Association to support advances.Check out this conversation if you're concerned about your brain health, that of family members getting older, or if you're just concerned about the future of the country with experts predicting the number people over 65 will increase dramatically in the very near future.**After this episode was recorded, the Centers for Medicare and Medicaid Services affirmed its decision to limit coverage of Aduhelm.Show links - Percy Griffin's bio- The Alzheimer's Association's Part the Cloud program- The paradox of dementia rates decreasing- The argument for focusing more resources on improving institutions and social processes for brain health- Recent research on napping- The Alzheimer's Association helpline- ALZConnected, a free online community for people affected by dementia - TrialMatch for people with dementia and healthy volunteers to find clinical trials for Alzheimer's and other de

Chinese immuno-oncology companies are changing how they interact with FDA as they seek approval of PD-1 programs. On this episode of BioCentury This Week, BioCentury's editors discuss takeaways from a survey of CEOs and R&D heads developing PD-1 or PD-L1 inhibitors about what's next for their programs. The team also previews translational data expected at next month's meeting of the American Association for Cancer Research (AACR) and legislation making its way through Congress as the House Energy and Commerce Committee's health subcommittee prepares to gather. This week's podcast is sponsored by life sciences investment firm Jeito Capital. 

Biden addressed the Nation on March 1, 2022. We cover his main gaffes, giraffes, and schemes. Starring Nancy Pelosi as the Joker and VP Kamal as a burlap sack. Topics covered: Healthcare Prices, Competition with China, Veterans, Ukraine, Supreme Court, 80 Bipartisan Bills, End Cancer through ARPA-H

John Murphy is the Vice President of the Biotechnology Innovation Organization (BIO), the largest trade association in the world representing biotechnology companies. John's role encompasses all legal issues impacting healthcare biotechnology and is an expert on topical issues such as intellectual property, drug pricing, and legislation in the biopharma sector. In this podcast we discuss the drug pricing proposals included in President Biden's signature legislation, Build Back Better. While many in the general public feel that it's only fair that Medicare start to negotiate drug pricing similar to what is done in the EU to control the out of pocket costs of medicines, John Murphy highlights what this would mean practically for the biotech sector, highlighting that even if drug price controls appear reasonable on the surface, there are inevitable trade-offs. Build Back Better will likely place severe constraints on the global innovation ecosystem in the development of needed therapies for orphan conditions as well as for diseases like oncology and Alzheimer's disease. The discussion also highlights the need for a robust private sector to take-on the risks of development, and how many proposals such as the new $3 bil innovation public private partnership called ARPA-H are not likely to lead to meaningful leaps in innovation. Further, we discuss the implications of ‘Operation Warp Speed', and how the possibility to rapidly deliver needed mRNA vaccines to market in only 9 months could serve as a blueprint for addressing seemingly intractable issues such as antimicrobial resistance.

Richard Moscicki is the Executive Vice President for Science and Regulatory Advocacy and the Chief Medical Officer at Pharmaceutical Research and Manufacturers of America (PhRMA). Previously he was the Deputy Center Director for Science Operations for the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) and the Chief Medical Officer at Genzyme Corporation. In this podcast, we discuss the U.S. R&D ecosystem and the vital roles that NIH and the private sector play in bringing new therapies to patients. Richard was previously at Massachusetts General Hospital (MGH) and Harvard Medical School, and this strong academic background combined with his industry knowledge gives him a unique perspective on both sides of public and industrial R&D, as well as how NIH developed intellectual property moves from the ‘Eureka' phase to becoming an actual medicine. Our conversation includes President Biden's new $6.5 billion proposal called ARPA-H, modeled on DARPA, specifically for drug discovery, and where those efforts would be best directed to facilitate needed medicines to address unmet medical needs. We also touch on how the rapid evaluation and approval of vaccines for COVID-19 could serve as an improved regulatory blueprint for accelerated evidence driven access to patients.

Don't forget to subscribe. --- Send in a voice message: https://anchor.fm/beau-of-the-fifth-column/message Support this podcast: https://anchor.fm/beau-of-the-fifth-column/support

"Long COVID" is the name for the phenomenon experienced by people who have "recovered" from COVID-19 but are still suffering from symptoms months after the virus invaded their bodies. In this episode, listen to highlights from a 7 hour hearing in Congress about Long COVID so that you can recognize the disease and know where to turn for treatment. Even if you didn't catch the rona yourself, Long COVID is far more common that you probably think and is almost certainly going to affect someone you know. Executive Producer: Michael Constantino Please Support Congressional Dish – Quick Links Click here to contribute monthly or a lump sum via PayPal Click here to support Congressional Dish via Patreon (donations per episode) Send Zelle payments to: Donation@congressionaldish.com Send Venmo payments to: @Jennifer-Briney Send Cash App payments to: $CongressionalDish or Donation@congressionaldish.com Use your bank's online bill pay function to mail contributions to: 5753 Hwy 85 North, Number 4576, Crestview, FL 32536 Please make checks payable to Congressional Dish Thank you for supporting truly independent media! Recommended Episodes CD145: The Price of Health Care Articles/Documents Article: Why Impact of ‘Long Covid' Could Outlast the Pandemic, By Jason Gale, Bloomberg, The Washington Post, June 8, 2021 Article: Long covid has lasted over a year for 376,000 people in the UK, By NewScientist, June 4, 2021 Article: Long-COVID-19 Patients Are Getting Diagnosed With Rare Illnesses Like POTS, By Cindy Loose, Kaiser Health News, TIME, May 27, 2021 Article: Long Covid symptoms ease after vaccination, survey finds, By Natalie Grover, The Guardian, May 18, 2021 Article: A pandemic that endures for COVID long-haulers, By Alvin Powell, The Harvard Gazette, April 13, 2021 Article: Atlantic Council urges Biden to enforce regime change in Belarus, By Centers for Medicare & Medicaid Service News Release: Secretary Sebelius Announces Senate Confirmation of Dr. Francis Collins as Director of the National Institutes of Health, National Institutes of Health, August 7, 2009 Sound Clip Sources Hearing: THE LONG HAUL: FORGING A PATH THROUGH THE LINGERING EFFECTS OF COVID–19, House Committee on Energy and Commerce, April 28, 2021 Watch on Youtube Witnesses: Francis Collins, M.D., Ph. D. Director of the National Institutes of Health John T. Brooks, M.D. Chief Medical Officer for COVID-19 Response at the Centers for Disease Control and Prevention Steven Deeks, M.D. Professor of Medicine at the University of California, San Francisco Jennifer Possick, M.D. Associate Professor at Yale School of Medicine Director of Post-COVID Recovery Program at the Winchester Center for Lung Disease at Yale-New Haven Hospital Natalie Hakala COVID patient Lisa McCorkell COVID patient Chimere Smith COVID patient Transcript: 1:01:34 Francis Collins: We've heard troubling stories all of us have people who are still suffering months after they first came down with COVID-19, some of whom initially had very few symptoms or even none at all. And yet today these folks are coping with a long list of persistent problems affecting many different parts of the body, fatigue, brain fog, disturbed sleep, shortness of breath, palpitations, persistent loss of taste and smell, muscle and joint pain, depression and many more 1:02:35 Francis Collins: I would like to speak directly to the patient community. Some of you have been suffering for more than a year with no answers, no treatment options, not even a forecast of what your future may hold. Some of you have even faced skepticism about whether your symptoms are real. I want to assure you that we at NIH hear you and believe you. If you hear nothing else today here that we are working to get answers that will lead to ways to relieve your suffering. 1:03:13 Francis Collins: New data arrived every day. But preliminary reports suggested somewhere between 10 to 30% of people infected with SARS COVID2 to may develop longer term health issues. To get a solid measure of the prevalence, severity and persistence of Long COVID we really need to study 10s of 1000s of patients. These folks should be diverse, not just in terms of the severity of their symptoms and type of treatment received, but in age, sex, race and ethnicity. To do this rapidly, we are launching an unprecedented metacohort. What is that? Well, an important part of this can be built on existing longitudinal community based cohorts are also the electronic health records of large healthcare systems. These resources already include 10s of 1000s of participants who've already contributed years worth of medical data, many of them will by now suffer from long COVID. This approach will enable us to hit the ground running, giving researchers access to existing data that can quickly provide valuable insights on who might be most at risk, how frequently individual symptoms occur, and how long they last. 1:04:24 Francis Collins: Individuals suffering with long COVID including those from patient led collaborative groups will be invited to take part in intensive investigation of different organ systems to understand the biology of those symptoms. Our goal is to identify promising therapies and then test them in these volunteers. 1:05:07 Francis Collins: Finally we need a cohort for children in adolescence. That's because kids can also suffer from long COVID and we need to learn more about how that affects their development. 1:05:35 Francis Collins: As we recruit volunteers, we will ask them to share their health information in real time with mobile health apps and wearable devices. 1:08:09 John Brooks: Although standardized case definitions are still being developed, CDC uses the umbrella term Post COVID conditions to describe health issues that persist for more than four weeks after a person is first infected with SARS-CoV-2 to the virus that causes COVID-19. Based on our studies to date, CDC has distinguished three general types or categories of post COVID conditions, although I want to caution that the names and classifications may change as we learn more. The first called Long COVID involves a range of symptoms that can last for months. The second comprises long term damage to one or more body systems or an organ and the third consists of complications from prolonged treatment or hospitalization. 1:09:45 John Brooks: Among these efforts are prospective studies that will follow cohorts of patients for up to two years to provide information on the proportion of people who develop post COVID conditions and assess risk factors for their development. 1:10:00 John Brooks: CDC is also working with multiple partners to conduct online surveys about long term symptoms and using multiple de-identified electronic health record databases to examine healthcare utilization of patient populations after initial infection. 1:20:21 John Brooks: Not only are there persons who develop post COVID symptoms, who we later through serology or testing recognizes having had COVID. But there's also there also were people who develop these post COVID conditions who have no record of testing, and we can't determine that they had COVID. So we've got to think carefully about what that how to manage that when we're coming up with a definition for what a post COVID condition is. 1:20:55 John Brooks: One of the most important things is to make sure that this condition is recognized. We need to make sure that folks know what they're looking at, as you've heard it's sort of protean. There are all sorts of different ways. Maybe we'll talk about this later. But the symptoms and ways that people present are very varied. And people need to be thinking, could this be post COVID and also taking patients at their word. You know, we've heard many times of patients have been ignored or their symptoms minimized, possibly because they didn't recognize that and COVID previously. 1:24:33 John Brooks: It's common, it could be as common as two out of every three patients. Study we recently published in our flagship journal, the Morbidity and Mortality weekly report suggested two out of three patients made a clinical visit within one to six months after their COVID diagnosis. So that is unprecedented, but people who've recovered from the flu or a cold don't typically make a scheduled visit a month later. It does seem that for some people, that condition gets better but there are definitely a substantial fraction of persons in whom this is going on for months. 1:25:37 Francis Collins: Basically what we did was to think of all of the ways in which we could try to get answers to this condition by studying people, both those who already have self identified as having long COVID, as well as people who just went through the experience of having the acute illness to see what's the frequency with which they ended up with these persistent symptoms. And if you look around sort of what would be the places where you'd find such large scale studies, one would be like we were just talking about a minute ago, with Mr. Guthrie, the idea of these long standing cohort studies, Framingham being another one where you have lots of people who have been followed for a long time, see if you can learn from them who got long COVID. And what might have been a predisposing factor that's part of the medical work. You could also look at people who have been in our treatment trials, because there are 1000s of them that have enrolled in these clinical trials. And they've got a particular treatment applied like a monoclonal antibody, for instance, it would be really interesting to see if that had an effect on how many people ended up with long COVID did you prevent it, if you treated somebody acutely with a monoclonal antibody, and then there are all these patient support groups, and you'll be hearing more for them in the second panel, were highly motivated, already have collected a lot of data themselves as citizen scientists, we want to tap into that experience and that wise advice about how to design and go through the appropriate testing of all this. So you put those all together, and that's a metacohort, where you have different kinds of populations that are all put together in a highly organized way with a shared database and a shared set of common data elements so we can learn as quickly as possible. 1:32:59 John Brooks: Extreme fatigue. I mean fatigue, as you probably heard, so bad, you can't get out of bed, it makes it impossible for you to work and limits your social life, anxiety and depression, lingering, chronic difficulty breathing with either cough or shortness of breath. That loss of smell persists for a very long time, which incidentally is particularly unique to this infection to the best I know. 1:37:10 Francis Collins: So the idea of trying to assemble such a large scale effort from multiple different kinds of populations of patients, is our idea about how to do this quickly and as vigorously and accurately as possible. But it won't work if we can't actually compare across studies and figure out what we're looking at. So part of this is the ability to define what we call common data elements, where the individuals who are going to be enrolled in these trials from various sources have the same data collected using the same formats so that you can actually say, if somebody had shortness of breath, how did you define that? If somebody had some abnormality in a lab test, what were the units of the lab test that everybody will agree so you can do apples to apples comparisons? That's already underway, a part of this metacohort is also to have three core facilities. One of those is a clinical sciences core, which will basically come up with what are the clinical measures that we want to be sure we do accurately on everybody who's available for those to be done. Another is the data sciences core, which will work intensively on these common data elements and how to build a data set that is both preserving the privacy and confidentiality of the participants, because these are people who are human subject participants in a trial, and also making sure that researchers have access to information that they can quickly learn from. And then there's a third core, which is a bio repository where we are going to be obtaining blood samples and other kinds of samples. And we want to be sure those are accurately and safely stored. So they can be utilized for follow up research. All of that has to fold into this. And so I'm glad you asked that question. That is the mechanism by which we aim to make the whole greater than the sum of the parts here even though the parts are pretty impressive. The whole is going to be pretty amazing. 1:41:03 Francis Collins: Tomorrow is the one year anniversary of the launch of RADX, Rapid Acceleration and Diagnostics. Another program made possible by the Congress by providing us with some additional funds to be able to build new platforms for technology to detect the presence of that SARS COVID-2 virus, increasingly being able to do those now as point of care instead of having to send your sample off to a central laboratory. And even now doing home testing, which is now just in the last month or so become a reality and that's RADX that developed those platforms. 1:41:30 Francis Collins: It was a pretty amazing experience actually. 1:41:40 Francis Collins: We basically built what we call the shark tank. And we became venture capitalists. And we invited all of those people who had really interesting technology ideas to bring them forward. And the ones that looked most promising, got into the shark tank and got checked out by business people, engineers, various other kinds of technology experts, people who knew about supply chains and manufacturing and all of that to make sure that we put the funds into the ones that were most promising. And right now, today, Congressman, there's about 2 million tests being done today, as a result of RADX that otherwise would not have been. 2 million a day, or 34 different technologies that we put through this innovation funnel. And that has opened up a lot of possibilities for things like getting people back to school where you have testing capacity that we didn't have before. 1:42:32 Francis Collins: What did we learn about that that applies to long COVID? Well, one thing I learned was we can do things at NIH in really novel ways that move very quickly when we're faced with a crisis like COVID-19 pandemic, we're applying that same mentality to this effort on long COVID normally would have taken us more than a year to set up this kind of metacohort. We're doing it in a couple of months because we need to utilizing some of those same mechanisms that you gave us in the 21st Century CARES bill, which has been a critical part of our ability to move swiftly through something called Other Transactions Authority. 1:43:16 Francis Collins: You saw in the President's budget proposal for FY-22, something called ARPA H, which is basically bringing the DARPA attitude to health that also builds on these experiences and will give us, if approved by the Congress, the ability to do even more of these very rapid, very ambitious, yes, high risk, but high reward efforts as we have learned to do in the face of COVID and want to continue to do for other things like Alzheimer's disease, or cancer or diabetes, because there's lots of opportunities there, too. 2:02:53 John Brooks: The number of people seeking care after recovering from COVID is really unprecedented. And it's not just people who had severe COVID it may include people had very mild COVID and in fact, we know there's a number of people who never had symptomatic COVID who then get these long symptoms. 2:03:09 John Brooks: Just historically, the other disease I can think of that may have a little analogy to this is polio. It was a more devastating sequentially that people lived with the rest of their lives. But it was thanks to the enrollment of some early cohorts of these patients followed over the course of their life, that when post polio syndrome later came up in the population, we had the wherewithal to begin to understand it. And it happens with been a condition in many ways, sharing some characteristics of this post COVID condition. 2:16:33 Francis Collins: The virus has been evolving. So one question is, how long will you be immune to the same virus that infected you the first time. And we think that's probably quite a few months. But then are you immune to a variant of that virus that emerges like the one called B117, which now is almost 60% of the isolates we're seeing in the United States after it ran through the UK and then came to us, that degree of immunity will be somewhat lower. The good news here, though, is that, and this may surprise people, the vaccine actually provides you with better broad immunity, then the natural infection, and you don't quite expect that to be the case. Usually, you would think natural infection is going to be the way that revs your immune system to the max and the vaccine is like the second best, it's flipped around the other way in this case, and I think that's because the vaccine really gets your immune system completely awake. Whereas the natural infection might just be in your nose or your respiratory tree and didn't get to the rest of your body. With a vaccine. We think that immunity lasts at least six months. But is it longer than that? We don't know yet because this disease hasn't been around long enough to find that out. And so far, the vaccines, the Pfizer, the Moderna, do seem to be capable of protecting against the variants that are now emerging in the US like this B117. 2:26:09 John Brooks: Anosmia are the loss of smell or change and smell is an often overlooked, but surprisingly common problem among people. This disease really seems to target that and cause it. I can say this, you know, I've been I've had a particular interest in this topic, the reading that I've been doing seems to suggest that the virus isn't necessarily targeting the olfactory nerves, the nerves that transmit smell, but more of the nerves that are sort of around in supporting those nerve cells, and it's the swelling and the inflammation around those cells that seems to be leading to some kind of neurologic injury. I will say the good news is that many people will eventually recover their sense of smell or taste, but there are others in whom this is going to be a permanent change in terms of treatment, smell training, interesting therapy, but it really works. And it's I really want to raise people's awareness around that because the earlier you can begin smell training, the better the chances that you'll recover your sense of smell. 2:43:13 John Brooks: We hold regular webinars and calls for clinicians they can call into these often are attended by 1000s of providers. We use these as an opportunity to raise awareness because I think you made a really critical point that patients feel like their doctors don't recognize their problem or they don't accept that it's possible they have this condition. We use those calls and webinars to raise awareness that this is a real entity. We also then publish papers and put out guidelines that illustrate how to diagnose and begin to pull together what we know about management. 2:52:27 Francis Collins: But it certainly does seem that the risk of developing Long COVID goes up. It's fairly clear that the initial seriousness of the initial illness is somewhat of a predictor. Certainly people are in the hospital have a higher likelihood of long COVID than people who stayed out of the hospital but people who weren't hospitalized can still get it. It's just at a somewhat lower rate. 2:53:07 Francis Collins: Risk factors. older age people higher likelihood, women have a slightly higher chance of developing long COVID than men. BMI, obesity also seems to be a risk for the likelihood of long COVID. Beyond that, we're not seeing a whole lot of things that are predictive. And there must be things we don't know about yet. That would give you a chance to understand who's most vulnerable, to not be able to just get this virus out of there and be completely better, but we don't know the answer is just yet. 3:29:30 Francis Collins: First of all, let me say anxiety and depression is a very common feature of long COVID. But there are instances of actual induction of new psychoses sees individuals who previously were normally functioning who actually fall really into a much more serious psychiatric illness. We assume there's must be some way in which this virus has interfered with the function of the brain maybe by affecting vascular systems or some other means of altering the the way in which the brain normally works. But we have so little information right now about what that actual anatomic mechanism might be. And that's something we have to study intensively. 3:33:13 Francis Collins: When you look at what is the likelihood that somebody who is just diagnosed with COVID-19 is going to go on too long COVID It looks as if it's a bit higher for older people, but on the other hand, they're more young people getting infected. So if you go through the mathematics, you can see why it is that long. COVID seems to be particularly prominent now. And younger people who may not have been very sick at all with the acute infection, some of them had minimal symptoms at all, but now are turning up with this. 3:34:10 Francis Collins: We have 32 million people who've been diagnosed with the acute infection. SARS-COVI-2 to COVID-19. Let's say 10% is right. That means there are 3 million people going to be affected with this are already are and whose long term course is uncertain and may very well be end up being people with chronic illnesses. 3:35:07 John Brooks: It's a great opportunity to remind young people they're not immune to this right? This is really the audience you want to reach. Vaccination is something you should strongly consider. This affects people like you. 3:44:06 John Brooks: Some of the symptoms are the ones you see in adults, as you would expect, particularly pulmonary conditions, persistent shortness of breath, maybe cough, as well as persistent fatigue. There is also some evidence that he experienced what is called a brain fog, but it's probably some issue or probably neurocognitive in nature. And this is important for kids when they're growing and developing that, that we understand what's happening there because we don't want that to impair their ability to learn and grow properly. 4:35:54 Lisa McCorkell: I'm testifying today as a long COVID patient and as a member at the leadership team of the patient led research collaborative, a group of long COVID patients with backgrounds in research, policy and data analysis, who were the first to conduct research on Long COVID. My symptoms began on March 14 2020. Like many of what we call first waivers, I was not afforded a COVID test, because at the time tests were limited to hospitalized patients and those with shortness of breath, cough and fever, the last of which I didn't have. I was told that I had to isolate and within two weeks I'd be recovered. A month later, I was in worse health than in that initial stage. I couldn't walk more than 20 seconds without having trouble breathing, my heart racing and being unable to get out of bed the rest of the day. 4:37:18 Lisa McCorkell: Our ost recent survey asked about 205 symptoms over seven months and received almost 7000 responses. In our recent paper, 92% of respondents were not hospitalized, but still experienced symptoms in nine out of 10 organ systems on average. We found that patients in their seventh month of illness still experienced 14 symptoms on average. Most commonly reported were fatigue, post exertional, malaise and cognitive dysfunction. In fact, 88% experienced cognitive dysfunction and memory loss impacting their ability to work, communicate and drive. We found that this was as likely an 18 to 29 year olds as those over 60. Lesser known symptoms include tremors, reproductive changes, months long fevers and vertigo. Over two thirds require a reduced work schedule or cannot work at all due to their health condition. 86% experienced relapses were exerting themselves physically or mentally can result in a host of symptoms returning. 4:38:14 Lisa McCorkell: Long COVID is complex, debilitating and terrifying. But patients aren't just dealing with their symptoms. They're dealing with barriers to care, financial stability and recovery. Due to the lack of a positive COVID test alone, patients are being denied access to post COVID clinics, referrals to specialists, health insurance coverage, COVID related paid leave, workers comp, disability benefits, workplace accommodations and participation in research. When we know that not everyone had access to COVID testing that PCR tests have false negative rates of 20 to 40%. That antibody tests are more accurate on men and people over 40 and that multiple studies have shown that there's no difference in symptoms between those with the positive test and those without. Why are we preventing people who are dealing with real symptoms from accessing what they need to survive? 4:39:00 Lisa McCorkell: Even with a positive test patients are still being denied benefits or have to wait months until they kick in. Medical bills are piling up. People are being forced to choose between providing for themselves and their family and doing what's best for their body. 4:39:58 Lisa McCorkell: The stimulus checks that you all provided us to get through the pandemic. I do really appreciate them. But every cent of mine was spent on urgent care and doctor's visits where I was repeatedly told that mycotic cardio my inability to exercise and brain fog was caused by anxiety and there was no way that I could have had COVID since I didn't have a positive test. 4:41:37 Jennifer Possick: I hope to share my perspective as a pulmonologist caring for people with post COVID disease including Long COVID. So in Connecticut, the surge initially arrived in March of 2020. And within weeks thereafter, people were reaching out to us about patients who remained profoundly short of breath after their acute illness had passed. My colleagues and I were struck by how difficult it was to tell the difference between people recovering from mild, acute COVID and those who had required ICU level care. Both groups had the physical, cognitive and psychological fallout we would expect from a critical illness or a prolonged intubation. And in addition to being short of breath, they reported a host of other symptoms. I saw a teacher who had recurrent bouts of crushing chest pain, mimicking a heart attack, a young mother, who would have racing heartbeat and dizziness every time she played with her toddler, a local business owner who couldn't remember the names of his long term customers or balance his books, and a home health aide who didn't have the stamina or strength to assist her elderly clients. 4:42:53 Jennifer Possick: We've spent this year learning alongside our patients, about half of whom are never hospitalized. They are mostly working age, previously high functioning. Many were frontline or essential workers. Many were initially disbelieved. Their quality of life has been seriously impacted. Some can't walk to the mailbox or remember a shopping list, much less resume their everyday lives and work. 4:43:16 Jennifer Possick: They've used up their paid sick leave. They've cut back their hours they have left or lost jobs. They have difficulty accessing workman's compensation benefits and FMLA or securing workplace accommodations. Some have even cut back on food, rent or utilities to pay for mounting medical expenses. 4:44:03 Jennifer Possick: Consensus practice supports many forms of rehabilitation services but insurance approval and coverage have been beyond challenging and demand outpaces availability in any case. For patients with ongoing oxygen needs, requests for portable oxygen concentrators can be delayed or even denied complicating physical recovery and mobility. 4:44:27 Jennifer Possick: We are a well resourced program at an academic medical center. But we are swamped by the need in our community. This year, we have seen more patients with post COVID-19 conditions in our clinic alone then we have new cases of asthma and COPD combined. Looking ahead, the magnitude of the challenge is daunting. There are over 31 million survivors of acute COVID-19 in the United States, and we don't know how many people will be affected, what kind of care they will need, or how long, or what kind of care that will entail or how long they'll need it. Research will ultimately help us to understand the origin of the symptoms and to identify effective treatment, but in the meantime, their care cannot wait. 4:49:37 Steven Deeks: First, we don't have a way of measuring this, right? Everyone everyone has got a cohort or a clinic measures it differently. They report stuff differently. As a consequence, the epidemiology is a mess, right? We don't really have a good sense of what's going on we need and this has been said before, a general consensus on how to define the syndrome, how to measure it and study so that we can all basically be saying the same thing. Deeks we don't know prevanlence Deeks we don't know prevanlen... 270.5 KB 4:50:06 Steven Deeks: We don't really know the prevalence of either the minimally symptomatic stuff or the very symptomatic stuff. 4:50:27 Steven Deeks: Women in almost every cohort, women are more likely to get this than the men. And This to me is probably the strongest hint that we have in terms of the biology, because women in general are more susceptible to many autoimmune diseases and we know why. And so paying attention to that fact why it's more common in women I think is providing very important insights into the mechanism and is directing how we are going about our science to identify therapies. 4:51:09 Steven Deeks: The same time people are getting acute COVID. They're living in a society that's broken. There's lots of social isolation. There's lots of depression, there's lots of people struggling, who did not have COVID. And the way this social economic environment that we're living in, has interacted with this acute infection is likely contributing to what's happening in ways that are very important but I think ultimately going to be hard to untangle and something that has not been discussed. 6:00:36 Jennifer Possick: I don't think that we can broadly say that there is any treatment that is working for all patients. We don't have that answer yet. As Dr. Deeks had suggested, there are things we try empirically. Sometimes they work for some patients other times not, but we're not in a position yet to say that this is the regimen, this is the treatment that works. Cover Art Design by Only Child Imaginations Music Presented in This Episode Intro & Exit: Tired of Being Lied To by David Ippolito (found on Music Alley by mevio)

* An inside look at the insider “victims” who LOVE ransomware and use it for corporate profits. But how will government use it?* Calif county cuts COVID death toll by 25%, admitting the most obvious inflation aspects* Peggy Noonan, WSJ, pushed lockdown at beginning with an article, “Don't Panic is Rotten Advice”, now wants to inoculate you criticizing govt conspiracy theories — “What Drives Conspiracism”Christian persecution escalates in Canada and Australia* Trump called it HARPA, Biden calls it ARPA-H — same agenda from both of them to justify a digital dictatorship using health* Peter Daszak, the Professor Moriarty of pandemic conspiracy, will now investigate himselfTOPICS by TIMECODE1:05 Is ransomware “the biggest challenge since 9/11” as FBI just said? Let's look back 4 yrs ago when ATMs were being robbed and the banks used it to — make money. Cyberattacks have been used — and WILL be used in the future — to enrich corporations and empower politicians. In fact, they're PLANNING on it30:43 EFF, protecting privacy online, calls out PayPal for removing people with even LESS explanation than Google/Facebook/Twitter — and NO appeal. Imagine that! 39:18 How lockdown has created chaos in new cars and soaring prices for used cars: what we saw traveling cross-country and an empty Ford dealership just blocks away from the Ford factory that is packed with new cars nearly finished 42:39 Davos, Microsoft Will Use Cyber Hack False Flag To Do THIS. Their tactics and their goals — and how they plan to manipulate the public into begging for the next level of control on the internet — C2PA 45:54 Wearables & AI — The Coming Medical Dictatorship. The Trump-Biden bipartisan plan for “doctatorship”. Trump called it HARPA. Biden calls it ARPA-H. No difference. In fact, the same foundation is behind BOTH plans to constantly monitor you with WEARABLES, ANTICIPATE SICKNESS and take PRE-EMPTIVE action. What could possibly be wrong with that?58:06 Media will disappear Fauci's crimes like Microsoft search engine Bing disappeared “Tank Man” on the anniversary of Tiananmen Square1:08:42 Peter Daszak - the Professor Moriarty of the Wuhan lab. 1:19:35 California county admits it inflated COVID deaths by 25%. It's worse than they admit 1:22:56 WSJ's Peggy Noonan — who sold “PANIC” the day before lockdown is now back to expose what she calls “CONSPIRACISM”, i.e. any questioning of official government pronouncements. 1:32:25 More Christian persecution this weekend in the name of “health”. So why are many Christians, especially pastors, reluctant to speak out and resist in civil disobedience? What is the role of the Christian in this?1:43:00 Letters from listeners — asymmetric warfare, vaccine injuries, employer vaccine mandatesFind out more about the show and where you can watch it at TheDavidKnightShow.comIf you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughZelle: @DavidKnightShow@protonmail.comCash App at:  $davidknightshowBTC to:  bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Mail: David Knight POB 1323 Elgin, TX 78621

An inside look at the insider “victims” who LOVE ransomware and use it for corporate profits. But how will government use it? Calif county cuts COVID death toll by 25%, admitting the most obvious inflation aspects Peggy Noonan, WSJ, pushed lockdown at beginning with an article, “Don't Panic is Rotten Advice”, now wants to inoculate you criticizing govt conspiracy theories — “What Drives Conspiracism” Christian persecution escalates in Canada and Australia Trump called it HARPA, Biden calls it ARPA-H — same agenda from both of them to justify a digital dictatorship using health Peter Daszak, the Professor Moriarty of pandemic conspiracy, will now investigate himself TOPICS by TIMECODE 1:05 Is ransomware “the biggest challenge since 9/11” as FBI just said?  Let's look back 4 yrs ago when ATMs were being robbed and the banks used it to — make money.  Cyberattacks have been used — and WILL be used in the future — to enrich corporations and empower politicians.  In fact, they're PLANNING on it 30:43 EFF, protecting privacy online, calls out PayPal for removing people with even LESS explanation than Google/Facebook/Twitter — and NO appeal.  Imagine that! 39:18 How lockdown has created chaos in new cars and soaring prices for used cars: what we saw traveling cross-country and an empty Ford dealership just blocks away from the Ford factory that is packed with new cars nearly finished 42:39 Davos, Microsoft Will Use Cyber Hack False Flag To Do THIS.  Their tactics and their goals — and how they plan to manipulate the public into begging for the next level of control on the internet — C2PA 45:54 Wearables & AI — The Coming Medical Dictatorship.  The Trump-Biden bipartisan plan for “doctatorship”.  Trump called it HARPA.  Biden calls it ARPA-H.No difference.  In fact, the same foundation is behind BOTH plans to constantly monitor you with WEARABLES, ANTICIPATE SICKNESS and take PRE-EMPTIVE action.  What could possibly be wrong with that? 58:06 Media will disappear Fauci's crimes like Microsoft search engine Bing disappeared “Tank Man” on the anniversary of Tiananmen Square 1:08:42 Peter Daszak - the Professor Moriarty of the Wuhan lab. 1:19:35 California county admits it inflated COVID deaths by 25%.  It's worse than they admit 1:22:56 WSJ's Peggy Noonan — who sold “PANIC” the day before lockdown is now back to expose what she calls “CONSPIRACISM”, i.e. any questioning of official government pronouncements.  1:32:25 More Christian persecution this weekend in the name of “health”.  So why are many Christians, especially pastors, reluctant to speak out and resist in civil disobedience?  What is the role of the Christian in this? 1:43:00 Letters from listeners — asymmetric warfare, vaccine injuries, employer vaccine mandates Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation through Zelle: @DavidKnightShow@protonmail.com Cash App at:  $davidknightshow BTC to:  bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7 Mail:      David Knight      POB 1323      Elgin, TX 78621

In this episode of the Real World Talk podcast, Kevin Keogh talks to Matthew Ong, the Associate Editor at The Cancer Letter.With over eight years of experience in writing investigative and enterprise stories about oncology, cancer informatics, drug development, and medical devices, Matt has a direct insight into the industry and works alongside some of the smartest people in the field.Kevin and Matt discuss rapid tech advancements in oncology and how informatics and real-world evidence are shaping the industry. According to Matt, as long as we're careful about over-promising and we recognize the need for data sharing, technology will continue to help us deliver astonishing results.President Joe Biden's recent $6.5 billion proposal to create a new, cancer-focused health agency within the National Institutes of Health presents an opportunity to accelerate the development of a comprehensive data federation for cancer, Matt said. ARPA-H, or Advanced Research Projects Agency-Health, is expected to complement the National Cancer Institute's mission by funding more challenging, innovative initiatives that traditionally wouldn't be taken on through basic research grants or by a biotech startup.Lack of diversity in clinical trial data is another challenge left to tackle—Matt shares some real-life examples of how lack of diversity in trial samples results in faulty findings.Matt's predictions for the future are optimistic, and we're looking forward to more groundbreaking developments in the fight against cancer.